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Abbreviations 
 
APC Tumour suppressor adenomatous polyposis coli 
ATF6 Activating transcription factor 6  
ATG16L1 Autophagy-related gene16-like 
Atoh1 Atonal Homolog 1 
Axin 2 axis inhibition protein 
CARD15 Caspase recruitment domain-containing protein 15  
CD Crohn's disease 
c-Myc Myc proto-oncogene protein  
DAPI 4',6-diamidino-2-phenylindol 
 Defa-rs1 Alpha-defensin-related sequence 1  
DNBS/TNBS Di- and Trinitrobenzene sulfonic acid 
dNTP deoxy-nucleoside-triphosphate 
DSS Dextran sulphate sodium 
EGF Epidermal growth factor 
ER Endoplasmic reticulum 
ERK p42/44 extracellular signaling kinase 
FADD Fas-Associated protein with Death Domain  
GALT Gut associated lymphoid tissue 
GAPDH Glycerinaldehyde-3-phosphate-dehydrogenase 
GI Gastrointestinal 
GRP78 78 kDa glucose-regulated protein  
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H hour (s) 
Hbd-1 Human β-defensin 1 
HSP Heat shock protein  
i.p. Intraperitoneal 
IBD Inflammatory bowel disease  
IBD1 Inflammatory bowel disease protein 1  
IECs Intestinal epithelial cells 
iE-DAP 
 
γ-d-glutamyl-meso-dia-minopimelic acid  
IgA Immunoglobulin A  
IKK  inhibitor of Nf-κB kinase complex 
IL-1β interleukin-1 beta  
IRAK IL-1 receptor-associated kinase  
IRE Inositol-requiring enzyme  
JNK c-Jun N-terminal kinases 
Kb kilo -kase 
kDa kilo-Dalton 
loxP  locus of crossing over 
LP Lamina propria 
LRP5/6 Single-span low density lipoprotein receptor-related protein 5 or 6 
LRR C-terminal  leucine-rich repeat domain 
M minute(s) 
MAMPs Microbial-associated molecular patterns  
MAPK Mitogen-activated protein kinase 
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MAPK 
 
MAPK phosphatase  
MKK4 and MKK7 
 
Mitogen activated kinase kinases 4 and 7 
MLN Mesenteric lymph nodes 
 
mRNA messenger RNA 
mTORC1 Mammalian target of rapamycin complex 1  
MyD88 Adaptor myeloid differentiation primary response gene 88  
NAIP Baculovirus-inhibitor-of-apoptosis repeats domain for human neuronal apoptosis 
inhibitory protein  
NEMO  NF-κB essential modulator  
Nfκβ Nuclear factor kappa-light-chain-enhancer of activated B cells 
NOD1/2 Nucleotide-binding oligomerization domains 1 and 2  
Notch Neurogenic locus notch homolog protein (Notch) ligands 
PCR Polymerase Chain Reaction 
PERK Protein kinase RNA like ER kinase  
PPRs Pattern recognition receptors  
qPCR quantitative Realtime PCR 
Rac1 The small GTPases Ras-related C3 botulinum toxin substrate 1 
RegIIIγ Antimicrobial peptides regenerating islet-derived protein 3 gamma  
RELMβ Resistin-like molecule-β 
Rhoa Ras homolog gene family, member A 
RIP1/3 Receptor interacting proteins 1 and 3 
Rpm rotation per minute 
 
SDS  
 
Sodium Dodecyl Sulfate 
 SFB Segmented filamentous bacteria  
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TFF3 Trefoil factor 3 
Th17 T helper 17 cells  
TLRs Trans-membrane Toll-like receptors  
TNF Tumor necrosis factor 
TRAF6 TNF receptor-associated factor 6 
UC 
 
Ulcerative colitis 
 
 UPR Unfolded protein response  
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 Summary 
 
C-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein 
kinase (MAPK) family known to phosphorylate and activate several transcription factors, 
including c-Jun, ATF-2, activating protein-1 (AP-1), and p53. These signal transduction 
pathways that link to JNK play an important role in a variety of cellular processes, including 
inflammation, cell proliferation, differentiation, and apoptosis. The JNKs are encoded by 
three genes, JNK1, JNK2, and JNK3. JNK1 and JNK2 are ubiquitously expressed, whereas 
the expression of JNK3 is restricted to the brain, heart and testis. JNK pathway is considered 
to be a potentially relevant target for therapy for inflammatory bowel diseases. This study 
aimed to evaluate the role of JNKs in the intestine. 
For studying the role of JNKs in regulation of the gastrointestinal barrier in vivo we 
used knockout (KO) mice. Mice with a conditional IEC-specific Jnk1 and a complete Jnk2 
deletion were crossed to obtain a complete Jnk knockout in IECs (JNK1∆IEC /JNK2-/-). We 
analysed these mice during homeostasis and acute colitis and compared their phenotype 
with wild-type (WT) and single knockout mice (JNK1-/-, JNK2-/- and JNK1∆IEC) as well as chi-
meric JNK2-/- / WT animals generated by bone-marrow transfers. 
JNK1 and JNK2 are differently regulated in IECs. Basal levels of JNK1 and JNK2 are 
phosphorylated during homeostasis, whereas colitis-induced pJNK was exclusively encoded 
by JNK2.  Furthermore, JNK1 and JNK2 mediate different downstream functions. JNK2-
deficient mice showed enhanced IEC apoptosis and regenerative proliferation without per-
turbations of tissue homeostasis. During acute colitis JNK2-deficiency in non-hematopetic 
cells caused increased pathology, IEC apoptosis, Goblet cells loss, inflammation, ER stress 
and barrier dysfunction. JNK1 deficiency alone or in combination with JNK2 deletion showed 
no significantly aggravated colitis phenotype. Microarray analyses revealed distinct transcrip-
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tional profiles regulated by JNK1 and JNK2 with a preferential regulation of genes involved in 
apoptosis and proliferation by JNK2. 
Taken together our data indicate that upstream regulation and downstream effects of 
JNK1 and JNK2 in IECs show major differences.  We identify IEC-expressed JNK2 as an 
important cytoprotective factor in IECs. 
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Zusammenfassung 
 
C-Jun N-terminale Kinasen (JNKs) sind Mitglieder der MAP-Kinasen Familie (MAPK). 
Sie phosphorylieren und aktivieren verschiedene Transkriptionsfaktoren inbegriffen c-Jun, 
ATF-2, Aktivierungs -Protein-1 (AP-1) und p53. Diese Signaltransduktionskaskaden, welche 
maßgeblich von JNK beeinflusst werden, spielen eine wichtige Rolle bei einer Vielzahl von 
zellulären Prozessen wie Zellteilung, Zelldifferenzierung und Apoptose aber auch in Entzün-
dungsreaktionen. Die JNKs werden von 3 verschiedenen Genen kodiert: Jnk1, Jnk2 und 
Jnk3. Jnk1 und Jnk2 werden ubiquitär exprimiert, wohingegen die Expression von Jnk3 auf 
Herz, Gehirn und Hoden beschränkt ist. Die JNK Signalkaskade stellt ein potentiell relevan-
tes Ziel für die Therapie von chronisch entzündlichen Darmerkrankungen dar. In dieser Stu-
die wird die Rolle von JNKs im gastrointestinalen Trakt untersucht. 
Zur Untersuchung der Rolle von JNKs bei der Regulation der gastrointestinalen Bar-
riere  in vivo  wurden  knock-out (KO) Mäuse verwendet. Mäuse mit einem konditionalen 
knock-out für Jnk1 spezifisch in intestinalen Epithelzellen (IEZ) wurden mit Mäusen gepaart 
die eine gänzliche Deletion im Jnk2 Gen trugen. Ergebnis daraus waren Mäuse mit einer 
Totaldeletion von Jnk in den IEZ (JNK1∆IEC /JNK2-/-). Analysiert wurden Mäuse während Ho-
möostase und im Zustand aktiver Colitis und die Phänotypen von Wildtyp (WT) mit  single 
knock-out Mäusen verglichen (JNK1-/-, JNK2-/- and JNK1∆IEC). Anschließend wurden ebenso 
chimäre Tiere mittels Knochenmarkstransplantation generiert und untersucht (JNK2-/- / WT). 
JNK1 und JNK2 werden in IEZ unterschiedlich reguliert. Während Homöostase wer-
den JNK1 und JNK2 auf einen Basalniveau phosphoryliert, binnen Colitis sind exklusiv JNK2 
phosphoryliert vorzufinden. Darüber hinaus sind JNK1 und JNK2 Mediatoren verschiedener 
downstream Funktionen. JNK2 defiziente Mäuse wiesen vermehrte Apoptose in IEZ und 
erhöhte regenerative Proliferation auf ohne Störung der Gewebshomöostase. Während akti-
ver Colitis verursachte die JNK2 Defizienz in nicht-hämatopoetischen  Zellen ein verstärktes 
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pathologisches Bild, Apoptose von IEZ, Verlust von Becherzellen, Entzündung, ER Stress 
und Barriere Dysfunktionen. JNK1 Defizienz alleine oder in Kombination mit JNK2 Deletion 
zeigte keinen signikfikant verschlechterten Phänotyp. Eine Microarray Analyse zeigt deutlich 
abgegrenzte Transkriptionsprofile reguliert durch JNK1 und JNK2. Preferentiell werden Ge-
ne durch JNK2 reguliert die in Apoptose und Proliferation involviert sind. Zusammengefasst 
deuten unsere Daten darauf hin, dass die upstream Regulation und die downstream Effekte 
von JNK1 und JNK2 in IEZ große Unterschiede aufweisen. JNK2 exprimiert in IEZ fungiert 
hierbei als wichtiger zytoprotektiver  Faktor. 
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1 Introduction 
 
1.1 Anatomy and function of the digestive system  
 The main functions of the digestive system are the conversion of food into nutrients 
and elimination of wastes. The gastrointestinal (GI) tract of vertebrates is composed of the 
headgut, foregut, midgut, hindgut and ancillary organs such as the salivary glands, the 
pancreas and the liver. The headgut consists of the mouth and pharynx, parts for the initial 
preparation and swallowing of food. The foregut consists of an esophagus for the swallowing 
of food and a stomach that serves for its storage and beginning of digestion. The midgut or 
small intestine is the place for food digestion and the absorption of nutrients. It is lined with a 
single layer of epithelial cells that secrete mucus and fluids, contain enzymes helping the 
final stages of carbohydrate and protein digestion, and absorb nutrients from the lumen into 
the circulatory system. In mice and man it consists of duodenum, jejunum and ileum. In 
humans, the luminal surface area of small intestine is increased 10-fold by the presence of 
finger-like projections called villi and an additional 20-fold by the microvilli, resulting in a total 
surface area of 200 m2 [1]. The hindgut or large intestine is the final site of digestion and 
absorption of fluids prior to defecation of indigestible food products via the anus. It contains 
crypts of Lieberkühn with stem cells and specialized mucus, involved in host defense against 
the increasing density of microbes that colonize the GI tract [2]. It is composed of appendix, 
cecum, ascending/ transverse/ descending/ sigmoid colon and rectum. The colon absorbs 
vitamins, created by the bacteria - such as vitamin K, vitamin B12, thiamine and riboflavin. 
As the small intestine, the large intestine is lined with a single layer of epithelial cells, but it 
lacks villi and its absorptive cells lack digestive enzymes and the ability to absorb most 
nutrients. In addition to its functions in digestion, nutrient transport, exchange of water and 
electrolytes as well as hormone production, the intestinal epithelium has a role in defining 
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the barrier between the host and the external environment [3]. However, this barrier is not 
absolute and crosstalk occurs between the microorganisms and the mucosal tissues [3]. 
1.2 Mucosa and epithelial cells 
The tissue of the GI tract has several layers. From the luminal side to the outside 
these layers are the mucosa, submucosa, muscularis and serosa. The mucosa is subdivided 
into the epithelium, the underlying connective tissue known as the lamina propria (LP) and a 
thin layer of smooth muscles, the muscularis mucosae that divides the mucosa from the 
submucosa. The epithelium consist of a single layer of intestinal epithelial cells (IECs) that 
are closely attached to one another at their lumen-facing border by tight junctions, adherent 
junctions and desmosomes [4] making the border relatively impermeable for passive 
diffusion of the majority of nutrients. Water-soluble monosaccharides, amino acids, vitamins, 
and minerals are selectively transferred across the intestinal cell membranes by carrier-
mediated transport. Some carriers simply facilitate the diffusion of a substance down its 
concentration gradient; others are capable of transporting a nutrient against its concentration 
gradient, which requires either a direct or indirect investment of cellular energy [5].  
The GI barrier separates the mammalian host from the external environment. It is 
specially adapted for colonization by commensal bacteria that contribute to digestion and 
markedly influence the development and function of the mucosal immune system [6]. Key to 
the coexistence of commensal microbial communities and mucosal immune cells is the 
capacity to maintain the segregation between host and microorganism [7]. The intestinal 
epithelium accomplishes this with one layer of epithelial cells that forms physical and 
biochemical barrier separating lumen with food and bacteria antigens from submucosa. 
Furthermore, intestinal epithelial cells act as sensors for microbes and depending of 
bacteria-derived signals evoke appropriate immune responses, ranging from tolerance to 
anti-pathogen immunity.  
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In the base of the crypts reside pluripotent epithelial stem cells where the 
proliferation, differentiation and functional potential of epithelial cell progenitors is regulated 
by the local stem cell niche [6]. These cells proliferate to produce transit-amplifying cells, 
which can then divide several times before creating terminally differentiated epithelial cell 
lineages; absorptive enterocytes and three types of secretory cells: goblet cells, enteroendo-
crine cells and Paneth cells [8]. 
Goblet cells are laying scattered between other cells in the epithelium of the intestinal 
and respiratory tracts. They are abundant in colon tissue while in others they are present in 
small numbers. Goblet cells are glandular epithelial cells whose function is to secrete mucin 
glycoproteins, which dissolves in water to form a net-like polymer mucus layer  [9, 10].  It 
consists of a dense inner layer devoid of bacteria and a loose outer layer in which comensal 
bacteria reside [11]. The thickness of the two component mucus layer varies for different 
regions of the gut. In rats it is thickest in the colon (∼830 μm) and thinnest in the jejunum 
(∼123 μm) [10]. The thickness of the inner layer is an important physiological feature and 
has a role in susceptibility to pathogen induced inflammation [11]. Within the secretory 
granules of the goblet cells the mucins are covered by abundant negative charges,  which 
are masked by calcium ions. During exocytosis, a membrane pore opens to the outside of 
the cell, allowing calcium to diffuse out [12]. This results in an extremely rapid phase change 
based on repulsion of polyanionic charges and hydration, leading to expansion of the mucin 
gel [13]. Mucins are expressed in tissue and cell type specific manner and are classified into 
secretory and membrane-associated [14]. Gel-forming secretory mucins are MUC2, 
MUC5ac, MUC5b and MUC6 [14]. Intestinal mucosal epithelia cells also express epithelial 
membrane-bound mucins MUC1, MUC3, MUC4, MUC12, MUC13 and MUC17 [14]. The 
dominant mucin in the intestine, MUC2, is especially abundant in the colonic crypts [14]. The 
importance of mucin production by goblet cells is emphasized by the spontaneous 
development of colitis in Muc2-knockout mice [15]. At the age of 5 weeks, Muc2-knockout 
mice show clinical and histological signs of colitis with growth failure compared with Muc2-
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heterozygots and control littermates. As the mice aged, Muc2 gene-deficient mice develop 
even stronger colitis and show predisposition to inflammation-induced colorectal cancers 
[16]. The important role of mucosal barrier in innate host defence in humans was shown in 
studies with patients suffering from the major types of inflammatory bowel disease (IBD); 
Crohn’s disease (CD) and ulcerative colitis (UC) [17]. In patients with UC, expression and 
glycosylation of mucins and numbers of goblet cells are reduced indicating a decrease in 
secretory activity and protective function of the colon mucosa [18]. The pattern of mucin 
expression throughout the colon is even altered in inactive UC patients in the absence of 
inflammation suggesting a primary role of altered mucin production in the development of 
UC [18]. In contrast, patients with CD had moderate expression of mucins MUC2 and MUC3 
and increased expression of mucins MUC4 that was accompanied with increased mucin 
sulphation and gel layer thickness [17]. Overall, these results suggest a distinct regulation of 
mucin expression in different forms of IBD.  
The mucus contains a number of proteins that limit bacterial growth, such as the 
antibacterial proteins and IgA. It also traps bacteria preventing their penetration. Additional 
goblet cell-derived products, such as trefoil factor 3 (TFF3) and resistin-like molecule-β 
(RELMβ), further contribute to the regulation of a physical barrier in the intestine [7]. TFF3 
provides structural integrity to the mucus through mucin crosslinking and acts as a signal 
that promotes IEC repair, migration and resistance to apoptosis [19]. RELMβ promotes 
MUC2 secretion, regulate macrophage and T cell responses during inflammation and pro-
tects from nematode infection by directly inhibiting parasite chemotaxis [20].  
Enteroendocrine cells (EEC) are scattered as single cells throughout the intestinal 
tract, located within the intestinal crypts and villi, and comprising ~1% of the epithelial cell 
population [21]. Their key purpose is to act as sensors of luminal contents and to secrete 
multiple regulatory molecules which control physiological and homeostatic functions.  
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 Paneth cells were first described by Austrian physiologist Josef Paneth in 1888 as 
cytoplasmic granule-rich epithelial cells which reside in small clusters at the base of crypts of 
Lieberkühn in the small intestine [22]. They provide host defense against microbes through 
secretion of antimicrobial molecules into the lumen of the crypt [23]. Several proteins and 
peptides, including lysozyme, sPLA2, enteric α-defensins, cryptdin related sequence 
peptides, and angiogenin 4, with well documented antimicrobial activity have been localised 
to Paneth cell granules [24-26]. In humans, Paneth cells develop in the colon and small 
intestine at a gestational age of 13.5 weeks, and after 17 weeks of gestation Paneth cells 
are mainly confined to the small intestine [27]. In mice and rats, Paneth cells are present 
after birth as the intestinal crypts are forming [27].  
Defensins are small (29–45 amino acids in length) cationic peptides that have been 
divided into two main families, the α- and β-defensins, on the basis of the disulphide bond 
pairing pattern [28]. Synthesised as precursor polypeptides, they undergo post-
translationally modifications into mature active peptides. In humans, four neutrophil 
defensins (Hnp-1, -2, -3, -4) were identified first, followed by two enteric α-defensins (Hd-5, -
6), expression of which is normally restricted to Paneth cells in the small intestine [29]. 
Enteric α-defensins have been characterised in murine Paneth cells and are termed 
cryptdins (“crypt defensins”). In contrast with enteric α-defensins, human β-defensin 1 (Hbd-
1) and other members of the β-defensin family appear to be expressed by most epithelial 
cells of the small and large intestine [23]. Hbd-1 is expressed constitutively while Hbd-2 is 
induced by stimuli that activate the transcriptional factor nuclear factor kappa-light-chain-
enhancer of activated B cells (Nfκβ) [23]. Alpha-defensins have hydrophobic and positively-
charged domains that can interact with phospholipids in cell membranes. They can insert 
into membranes, where they interact with one another forming pores that disrupt membrane 
function inducing cell death. The fact that bacterial membranes have a higher concentration 
of negatively-charged phospholipids then eukaryotic membranes, allows defensins to bind 
and disrupt bacterial cells without effecting host cells. Paneth cells are stimulated to secrete 
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defensins when exposed to Gram positive and Gram negative bacteria or bacterial products 
such as lipopolysaccharides or muramyl dipeptide [30].  
 In addition to defensins, Paneth cells secrete lysozyme and phospholipase A2, both 
possessing antimicrobial activity [31]. This pool of secretory molecules gives Paneth cells a 
potent arsenal against a broad spectrum of agents, including bacteria, fungi and even some 
enveloped viruses. Lysozyme is an antibacterial protein that is found at significant 
concentrations in many human secretions, including tears, breast milk, saliva, and gastric 
and small intestinal secretions [29]. Lysozyme cleaves glycosidic bonds which stabilise 
peptidoglycans of bacterial membranes, resulting in bacterial lysis [29]. However, gram 
negative bacteria are relatively resistant to lysozyme because they form an outer membrane, 
which protects the underlying peptidoglycan cell wall. The likely importance of lysozyme in 
intestinal innate defence has been suggested by its lack in Paneth cells in newborn infants 
with necrotising enterocolitis, the lack of lysozyme may render these infants susceptible to 
bacterial translocation and subsequent sepsis syndrome [29]. 
Beyond the roles in innate immunity and host defence, new results revealed that 
Paneth cells are a major source of secreted growth factors, including Wnt and epidermal 
growth factor (EGF) and neurogenic locus notch homolog protein (Notch) ligands necessary 
for maintaining stem cell function [32]. These observations indicated that the interaction of 
Paneth cell with Lgr5+ stem cells may be important for homeostasis of self-renewing of small 
intestinal crypts. On the other hand conditional depletion of a transcription factor important 
for intestinal secretory cell differentiation Atonal Homolog 1 (Atoh1) [33] leading to Paneth 
cell ablation, has no significant effect on survival, proliferation and function of Lgr5-
expressing stem cells challenging the idea that Paneth cells are an essential component of 
the intestinal stem cell niche in vivo [34, 35]. This observation suggests that non-epithelial 
niche sources may compensate for the loss of Paneth cells.  
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1.3 Life and death in the intestinal epithelium 
A striking feature of the intestinal epithelium is its enormous self-renewing capacity 
[36]. It is completely replaced by newly generated cells within only 4–5 days. 
Undifferentiated stem cells proliferate within the crypt region of the small and the large 
intestines, then they undergo up to six rounds of cell division forming a pool of transit-
amplifying cells, which are already partially differentiated [37]. Intestinal epithelial progenitors 
then divide and differentiate into the different epithelial cells while migrating upwards along 
the crypt–villus axis. After 4–5 days, terminally differentiated cells reach the tip of the villi 
from where they are shed into the lumen. In contrast to all other differentiated epithelial cell 
types, Paneth cells escape the upward migration by an unknown mechanism and settle 
down at the crypt base [38]. Therefore, proliferation, differentiation and cell death are pro-
cesses that have to be tightly controlled. Excessive cell death might result in barrier defects 
and as a consequence uncontrolled access of bacteria into the gut wall might occur[39]. 
Aged epithelial cells, after travelling from the crypt base to the villus tip in the small intestine, 
or to the surface epithelial cuff in the colon, are thought to die from anoikis, a special form of 
programmed cell death by inappropriate adhesion to adjacent cells and basal extracellular 
matrix [40]. Although the precise mechanisms controlling this process of shedding 
associated cell death are still poorly understood, a number of studies implicate that this 
process is actively regulated and involves caspase-3, a central protease of the intrinsic and 
extrinsic apoptotic pathways [40]. Caspase-3 activation occurs together with morphological 
changes associated with cell shedding [41]. This theory has also been supported by recent 
experimental studies showing that excessive cell shedding induced by Tumor necrosis factor 
(TNF) administration could be inhibited if caspase activation is blocked [40, 41]. On the 
contrary, mice deficient for caspase-3 were described to show no morphological differences 
in the development of the GI tract [42] suggesting that caspase-3 might be dispensable for 
tissue homeostasis in the gut. The fact that mice deficient for key molecule of apoptosis 
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show little if any structural changes implies that apoptosis might not be required for epithelial 
turnover in the gut at least in the steady state [40]. These findings are in agreement with the 
hypothesis that epithelial cell shedding might be a rather passive process induced by the 
spatial constraints of densely packed epithelial cells at the villus tip and shedding associated 
cell death might be a consequence rather than a cause of shedding [40].  
 
Figure 1 The intestinal epithelial cell layer. Modified from Gunther, C. et al. [40].  
 
Although most studies have linked apoptotic cell death to the pathogenesis of GI 
disease, other forms of cell death like necrosis, pyroptosis (crucial type of cell death for con-
trolling microbial infection) or autophagy (described elswhere) might influence intestinal ho-
meostasis and inflammation [40, 43]. Until very recently, necrosis was considered a passive 
effect, secondary to cellular trauma like plasma membrane injury observed in intestinal 
ischaemia and infarction, as seen in patients with necrotising enterocolitis [44]. In general, 
necrosis can be observed under physiological stress, inflammation and infection and is 
caused by external environmental changes such as the occurrence of toxins, hypoxia, 
cytolysins and significant changes in temperature [45]. Recently, a new type of cell death, 
termed necroptosis has been discovered [46]. Cells undergoing necroptosis are showing the 
morphological features of necrosis. On the other hand, necroptosis differs from necrosis as a 
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passive mode of cell death as it shares with apoptosis the fact that it is highly regulated by 
an intracellular protein platform [47]. Support for a physiological relevance of necroptosis in 
vivo came from studies demonstrating that the targeted knock-outs of caspase-8 and Fas-
Associated protein with Death Domain (FADD) in IECs led to the development of spontane-
ous terminal Ileitis in mice. The phenotype was directly mediated by aberrant activation of 
receptor interacting protein 1 and 3 (RIP1 and RIP3) in IECs, two major inducers of necrop-
tosis [48-50].  
1.4 Signaling pathways in IECs 
  Normal development and adult epithelial homeostasis is regulated by different intra-
cellular signals that control cell proliferation, migration, differentiation, adhesion and death. 
One of these signals is the Wnt (Wingless-related integration site) pathway, first identified in 
1982 with the discovery of the proto-oncogene Int1 (now known as Wnt1) in mice [51]. 
Since then, the crucial role of Wnt–β-catenin signalling in normal development as well as 
throughout the life of the organism was demonstrated in many organs [52]. Wnts are se-
creted, cysteine-rich glycoproteins that act as short-range ligands to locally bind to and acti-
vate seven-span transmembrane protein Frizzled and the single-span low density lipopro-
tein receptor-related protein 5 or 6 (LRP5/6) [52, 53]. Key mediator of Wnt signaling is 
β-catenin, localized in multiple subcellular locations, including adherent junctions where it 
contributes to cell–cell contacts, the cytoplasm where its levels are tightly controlled, and 
the nucleus where it is involved in transcriptional regulation and chromatin modifications 
[54]. In the nucleus, β-catenin associates with members of the T cell factor family of 
transcription factors to modulate expression of target genes c-Myc, Cyclin D1, CD44 and 
axis inhibition protein (Axin 2) [55, 56]. In the absence of extracellular Wnt glycoproteins, a 
destruction complex, including the tumour suppressor adenomatous polyposis coli (APC), 
the scaffold protein AXIN, casein kinase I (CKI) and the glycogen synthase kinase 3β 
(GSK3β) target  β-catenin for ubiquitylation and proteasomal degradation [56]. Loss of func-
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tion mutations of the tumour suppressors APC or Axin 2 lead to accumulation of nuclear β-
catenin and induces the formation of intestinal adenomas [57-59]. Wnt signaling is required 
for gut tube formation during development and it is a dominant force in controlling cell fate 
along the crypt-villus axis in adult intestine [60]. Beside the classical β-catenin-dependent 
pathway Wnts can active β-catenin-independent cascade that involves the small GTPases 
Ras-related C3 botulinum toxin substrate 1(Rac1) and Ras homolog gene family, member 
A (Rhoa) as well as c-Jun N-terminal kinases (JNKs) some of which elicit a transcriptional 
response [53].  
For maintaining steady state during constant exposure to food and microbial antigens 
epithelial cells require strategies for processing of microbes and degradation of damaged 
organelles and malformed proteins. This is done by autophagy, a membrane-mediated intra-
cellular degradation process promoting cell survival during nutrient deprivation, oxidative 
stress, and endoplasmic reticulum (ER) stress, and is therefore critically important for the 
maintenance of cellular homeostasis [61]. Dysfunctional autophagy mechanism leads to 
chronic intestinal inflammation, such as inflammatory bowel disease [61]. Polymorphism of 
autophagy-related gene16-like (ATG16L1) has been identified as risks for IBD[62]. The pro-
cess of autophagy is divided in several stages: induction, nucleation, elongation, endoso-
mal/lysosomal docking and fusion with the autophagosome and degradation. The mammali-
an target of rapamycin complex 1 (mTORC1) is a key regulator of authophagy induction. 
Under steady state mTORC1 is active and represses authophagosome formation. Inactiva-
tion of mTORC1, e.g., by starvation, results in the de-repression of signaling pathways 
downstream of mTORC1 and results in translocation to the phagophore, an early membrane 
precursor to the mature authophagosome [62, 63] Next step includes Beclin 1 acting as a 
scaffold protein forming a complex with phosphatidylinositol 3-kinase VPS34 (Vps34 PI(3)K), 
its Vps15 subunit and Atg14. Elongation of the phagophore/early autophagosome mem-
brane requires the protein microtubule-associated protein 1A/1B-light chain 3 (LC3) and its 
processing to LC3-II. Lipidation of LC3 is a critical step in the formation and completion of 
Introduction 
19 
 
the autophagosomal membrane [61]. The Atg16L1 complex, conjugated in several ubiquiti-
nylation-like reactions, may facilitate the lipidation and incorporation of LC3 into the autoph-
agosomal membrane [62]. In the final stage, mature autophagosome get fused with endo-
somes and lysosomes resulting in degradation and recycling of its contents [62]. As men-
tioned above one of the stress signals that can induce autophagy is ER stress. The ER has 
a role in synthesis, posttranslational modifications and folding of proteins and different phys-
iological and pathological conditions like Ca2+ depletion, oxidative stress, hypoxia, high-fat 
diet, hypoglycemia, and viral infections may cause ER stress and the accumulation of mis-
folded proteins leading to the unfolded protein response (UPR) [64]. ER stress has been 
linked with an increasing number and wide variety of inherited and sporadic human diseases 
including neurodegenerative diseases, developmental disorders, cancer, diabetes, cystic 
fibrosis, infections and inflammatory disorders [65]. Depending on the nature of the stressor, 
ER stress is often transient and well controlled by appropriate UPR function; however, pro-
longed ER stress can have major implications for the protein production and ultimately may 
result in premature apoptosis [65]. A key element for triggering UPR pathways is the ER 
chaperone 78 kDa glucose-regulated protein (GRP78, also known as BIP), which activates 
three ER initiating sensors; inositol-requiring enzyme (IRE), protein kinase RNA like ER ki-
nase (PERK), and activating transcription factor 6 (ATF6) [65]. When misfolded proteins ac-
cumulate in the ER lumen they bind to BIP titrating away BIP from its interaction with trans-
membrane sensors and activating them. IRE1 is a transmembrane protein with an N-
terminal luminal sensor domain and a C-terminal cytosolic effector region that contains both 
kinase and endoribonuclease (RNase) domains. Under ER stress IRE1 gets trans-
autophosphorylated and RNase domain activated excising a 26 nt sequence from unsplised 
X-box binding protein 1 (Xbp1u), producing mature spliced (Xbp1s) mRNA. XBP1s regulates 
the transcription of several genes involved in ER quality control mechanisms, ER/Golgi bio-
genesis, as well as ER-associated protein degradation  components genes involved in redox 
homeostasis and oxidative stress responses [64]. As IER1, PERK also gets trans-
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autophosphorylated and phosphorylate eukaryotic initiation factor 2 alpha, resulting in in the 
rapid shut down of general translation, relieving the protein burden on the stressed ER [64]. 
After being released from BIP, ATF6 moves to the Golgi where it gets cleaved and released 
ATF6 into the cytoplasm, which induces ER stress-related gene expression [66]. The first 
link between ER stress and intestinal inflammation was shown with IER1b (IEC-specific iso-
form of IRE1) knockout mice that had increased susceptibility to chemically induced colitis 
[67]. The involvement of IRE1 pathway in colitis was also supported by XBP1 conditional KO 
mice [68, 69]. These mice develop spontaneous small intestinal inflammation and increased 
expression of ER stress genes. The authors also found that XBP1 deletion results in 
apoptosis of Paneth and goblet cells [68, 70]. Furthermore, XBP1 has been identified as 
genetic risk loci in IBD [68]. 
Fine tuning of all signaling pathways is an imperative role of IECs enabling strong pro-
tection during homeostasis and pathophysiological conditions.  
1.5 The microorganisms in the gut 
The intestine is open ecological system that is colonized by large number of microor-
ganisms called microbiota, microflora, or normal flora with a density of up to 1012 bacteria per 
gram of luminal content in the colon [71]. It is known that the human body contains tenfold 
more microbial cells (1014) than human cells [72]. In the distal gut the most abundant bacte-
ria populations belong to two bacterial phylotypes, Firmicutes and Bacteroites. They 
peacefully coexist with their hosts forming intimate relationship where host and microbes 
have co-evolved for mutually beneficial outcomes. The intestine provides a protected nutri-
ent-rich environment for microbes while the microbiota in return play a role in the synthesis 
of vitamins and degradation of certain nutrition such complex glycans, that cannot be suffi-
ciently metabolized by the digestive machinery of the host. Furthermore, the microbiota me-
tabolizes bile acids, host hormones as well as xenobiotics (compounds foreign to a living 
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organism like including host-targeted drugs and antibiotics) and play a fundamental role in 
the competitive inhibition of pathogens. Interestingly, germ-free mice develop normally in 
sterile animal facilities; however, they require 30% more nutritional energy intake to reach 
the same weight as animals with a normal gut flora [73]. It is very likely that an intestinal flora 
that provides such a tremendous increase in energy efficiency offers a strong evolutionary 
advantage.  
In recent years, the use of germ-free mice has provided critical evidence towards the 
essential role of the enteric bacteria on the postnatal maturation of the intestinal barrier and 
immune system [74]. Although the development of the gut immune system is initiated before 
birth by a genetic program its full development occurs only after birth and is largely driven by 
the microbiota. For instance, the four major structures that make up the gut associated 
lymphoid tissue (GALT)  including, mesenteric lymph nodes (MLN), peyers patches, cryp-
topatches and isolated lymphoid follicles, are all poorly developed in germ free mice [75]. 
Furthermore, the microbiota stimulates the full development of the intestinal epithelium, the 
maturation of innate defense mechanisms, and the activation of naive T and B cells into ef-
fector T cells and immunoglobulin A (IgA)-producing plasma cells that populate the gut lami-
na propria [76]. Consequently, germ free animals show decreased immune resistance to 
infection compared with conventionally colonized animals [77]. Although the understanding 
how the intestinal microbiota drives the development of the intestinal barrier and immune 
compartment remains still poor, some reports nicely show that distinct commensal strains 
play differential roles. For example some strains such as segmented filamentous bacteria 
(SFB) in mice are strong inducers of GALT development as well as  homeostatic B and T 
cell maturation [78-80]. The intestinal colonization occurs in narrow postnatal time window. 
This time window seems to be important for the balanced development of the gut immune 
system [81]. It has been suggested that a delayed microbial colonization as well as a general 
dysbiosis may cause a permanent disequilibrium in the immune system resulting in inflam-
matory conditions such as allergies, autoimmune diseases and IBD later in life [82]. 
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Achieving and keeping homeostasis in the gut requires an equilibrium between toler-
ating the microbiota and simultaneously remaining vigilant against the potential threats 
posed by these microorganisms [83]. Another challenge comes from the dynamic nature of 
the intestinal microbial composition. Dramatic shifts in community structure can be exoge-
nously induced by antibiotic treatment, dietary change and pathogens [84]. It has been sug-
gested that the influence of “western” diets on the microbiota are a major reason for the de-
velopment of many disease in high-income societies including inflammatory diseases but 
also obesity and metabolic syndrome. Although the evidences for this hypothesis are still 
rare, two recent studies revealed new exiting insight in this aspect. Surprisingly, artificial 
sweeteners that are classically used by diabetic patients disturbed the microbiota-host rela-
tionship leading to enhanced dysglycaemia [85]. Furthermore, emulsifiers from preserved 
food caused intestinal dysbiosis inducing low grade inflammation and metabolic syndrome 
[86].  
1.6 Sensing the microbiota 
To tolerate a microbiota or to react against potentially dangerous pathogens the 
eukaryotic intestinal cells must maintain surveillance over the microbiota and control its 
number and composition [87]. The epithelium is in constant communication with the luminal 
microbiota and the underlying dense network of innate and adaptive immune cells. IECs are 
structurally and functionally polarized, with an apical surface facing the intestinal lumen and 
a basolateral surface facing the the lamina propria. 
Specialised sentinel cells, called M cells, in the intestinal mucosa continuously monitor 
luminal microbes. M cells are found above lymphoid structure in the small intestine and co-
lon and they facilitate the transcellular transport of macromolecules, IgA complexes and mi-
crobes to the lamina propria. There, the cargo is picked up by antigen-presenting cells that 
process and present antigens to B and T cells  [88].  
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Further on, intestinal epithelial cells are equipped with variety of pattern recognition re-
ceptors (PPRs) that have ability to specifically recognize and bind distinct microbial 
macromolecular ligands designated as microbial-associated molecular patterns (MAMPs) 
such as lipopolysaccharide, flagellin, peptidoglycans and formylated peptides [88]. PPRs 
include trans-membrane Toll-like receptors (TLRs) which scan the extracellular space, 
whereas the nucleotide-binding domain and leucine-rich repeat containing receptors (NLRs) 
guard the intracellular cytoplasmic compartment leading to a variety of downstream signaling 
pathways (Figure 2). Mammalian TLRs comprise a large family consisting of more than 12 
members [89]. TLR2 recognizes a variety of microbial components, like lipoproteins / 
lipopeptides from various pathogens and peptidoglycans as well as lipoteichoic acids from 
Gram-positive bacteria. TLR2 forms heterophilic dimers with other TLRs such as TLR1 and 
TLR6, both of which are structurally related to TLR2 [90]. TLR4 is an essential receptor for 
LPS, a major component of the Gram-negative bacterial outer membrane while, TLR4 has 
been shown to be involved in the recognition of endogenous ligands, such as heat shock 
proteins (HSP60 and HSP70), the extra domain A of fibronectins, oligosaccharides of hyalu-
ronic acid, heparin sulfate and fibrinogen, but all of these endogenous ligands require very 
high concentrations to activate TLR4 [90]. Individual TLRs are differentially distributed within 
the cell, TLR1, TLR2 and TLR4 are expressed on the cell surface, in contrast TLR3, TLR7, 
TLR8 and TLR9 have been shown to be expressed in intracellular compartments such as 
endosomes [91, 92]. TLR9 is essential in CpG DNA recognition, TLR3 is implicated in the 
recognition of viral dsRNA, whereas TLR7 and TLR8 are implicated in viral-derived ssRNA 
recognition and TLR5 recognizes bacterial flagellin [90]. A key molecule in the TLR signaling 
pathway is the cytoplasmic TIR domain containing adaptor myeloid differentiation primary 
response gene 88 (MyD88). Upon stimulation, MyD88 recruits IL-1 receptor-associated 
kinase (IRAK). IRAK is activated by phosphorylation and then associates with TNF receptor-
associated factor 6 (TRAF6), leading to the activation of two distinct signaling pathways, and 
finally to the activation of the transcription of NF-kB and JNKs [92]. Loss of epithelial MyD88 
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signaling resultes in increased numbers of mucus-associated bacteria, translocation of 
bacteria to MLNs, impaired mucus-associated antimicrobial activity and downregulation of 
expression of the polymeric immunoglobulin receptor (the epithelial IgA transporter), mucin 2 
and the antimicrobial peptides regenerating islet-derived protein 3 gamma (RegIIIγ) and 
alpha-defensin-related sequence 1 (Defa-rs1) [93]. Medzhitov and colleagues demonstrated, 
through the use of TLR- and MYD88-deficient and broad-spectrum antibiotic-treated mice, 
that commensal bacteria-derived signals contribute to epithelial homeostasis and repair in a 
model of chemically induced colitis using dextran sodium sulphate [94]. Furthermore, IEC-
specific deletion of molecules necessary for the activation of NF-κB downstream of TLR 
signalling in mice, including the inhibitor of NF-κB kinase (IKK) complex or NF-κB essential 
modulator (NEMO), results in development of  spontaneous colitis [95, 96]. Expression of 
TLRs in intestinal epithelial cells was shown to be different in patients suffering from IBD 
compared to healthy individuals. TLR2 and TLR4 are expressed at low levels by IECs in 
normal human colon tissues, TLR3  is abundantly expressed in normal human small 
intestine and colon, whereas TLR5 is expressed predominantly in the colon [97]. In active 
IBD, the expression of TLR3 and TLR4 was differentially modulated in the intestinal 
epithelium [97]. TLR3 was significantly downregulated in IEC in active CD but not in UC [97]. 
In contrast, TLR4 was strongly upregulated in both UC and CD, while TLR2 and TLR5 
expression remained unchanged in IBD [97]. These data suggest that IBD may be 
associated with distinctive changes in selective TLR expression in the intestinal epithelium, 
implying that alterations in the innate response system may contribute to the pathogenesis of 
these disorders [97]. 
Other major groups of innate immune sensors in IECs are NLRs. Upon activation of 
these sensors innate and adaptive immune cells are activated. These intracellular receptors 
are structurally composed of an N-terminal effector domain that can comprise caspase re-
cruitment domains (CARDs) as in the case of the NODs, a pryin domain as in the case of 
NLRP, or a baculovirus-inhibitor-of-apoptosis repeats domain for human neuronal apoptosis 
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inhibitory protein (NAIP) [98]. NLRs comprise a central oligomerization domain and a C-
terminal  leucine-rich repeat (LRR) domain and mediate signaling cascades through homo-
philic and heterophilic protein – protein interactions [98]. Nucleotide-binding oligomerization 
domains 1 and 2 (NOD1/2) are intracellular sensors of bacterial peptidoglycan components. 
NOD1 and NOD2 survey the cytosol for the presence of the peptidoglycan components di-
peptide γ-d-glutamyl-meso-dia-minopimelic acid (iE-DAP) and muramyl dipeptide (MDP), 
respectively. NODs drive the activation of mitogen-activated protein kinase (MAPK) and NF-
kB [99]. MAPK and NF-kB signaling leads to transcription of proinflammatory genes produc-
tion and defensins. Several polymorphisms of NOD2 are associated with Crohn disease. 
The most prominent ones are Arg702Trp, Gly908Arg and Leu1007fsinsC. These missense 
polymorphisms are located within the LRR domain of NOD2, involved in sensing MDP, and 
are associated with decreased MDP-induced NF-kB activity and impaired bacterial clearance 
[99]. A NOD2 gain of function mutation is also associated with a chronic systemic inflamma-
tory disorder known as “ Blau syndrome ” in which NOD2 is constitutively active and can 
cause ligand-independent activation of NF-kB [99]. In mice, the latter mutation enhances NF-
kB activation, apoptosis induction and secretion of interleukin-1 beta (IL-1β) in response to 
MDP, which was linked to increased susceptibility to bacteria-induced intestinal inflammation 
[99, 100]. NOD1-deficient mice are highly susceptible to infection with Helicobacter pylori 
[101], whereas NOD2-deficient mice are more susceptible to oral infection with Listeria mon-
ocytogenes [102].  These results emphasize that a balanced sensitivity of the innate recogni-
tion system is fundamentally important for the homeostasis of the host because loss-of-
function as well as gain-of-function mutations lead to disease states.  
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Figure 2 TRLs and NRLs signaling in IECs. Modified from Lavelle, E.C., et al. [98]. 
 
1.7 Inflammatory bowel disease 
Inflammatory bowel diseases (IBD) are group of inflammatory conditions of 
the gastrointestinal tract. The major types of IBD are Crohn's disease (CD) and ulcerative 
colitis (UC). These are chronic relapsing inflammatory disorder which involves an 
imbalanced host-commensal microbiota interaction [103]. Both diseases have 10-20x higher 
prevalence in individuals in Europe and North America with highest incidence in the devel-
oped urbanized countries [104]. Their first onset is generally in young adulthood (20 to 40 
years of age), peaking again at the age of 60-70 [105, 106]. The main difference between 
CD and UC is the location and nature of the inflammatory changes. CD, can involve any part 
of the gastrointestinal tract from the oropharynx to the perianal area, while the most fre-
quently affected part is the terminal ileum, whereas UC is a condition in which the 
inflammatory response and morphologic changes remain confined to the colon [107]. 
Microscopically, UC is restricted to the mucosa while CD affects the whole bowel wall. The 
cardinal symptom of UC is bloody diarrhea which may be associated with abdominal pain. In 
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the case of CD symptoms are stomach ache and diarrhea without blood. Both diseases may 
be accompanied by high temperature and weight loss as well as extra-intestinal complica-
tions affecting skin, joints liver and bile ducts.  
A variety of factors, which may be environmental, genetic, immunological and 
microbial in nature, contribute to the development of inflammatory bowel diseases [108, 
109]. However, the evidences suggest that cause of disease is rather combinations of these 
factors than the single one of them. The environmental factors are hygiene, dietary habits, 
geography and social status, smoking, drugs and stress. Remarkably, smoking has been 
identified as a risk factor for CD and a protective factor for UC indicating that distinct 
pathogenic mechanisms underlie each form of IBD [108, 110]. 
In the last decade many studies have been highly successful in identifying genes that 
contribute to disease susceptibility. In initial screening efforts, two groups identified NOD2 
(also designated caspase recruitment domain-containing protein 15 (CARD15) 
and  inflammatory bowel disease protein 1 (IBD1)) as a susceptibility gene in CD that is 
involved bacterial recognition as described above [111, 112]. Further on, several additional 
susceptibility loci have been implicated in IBD: inflammatory bowel disease protein 5 (IBD5), 
interleukin 23 receptor (IL23R) and ATG16L1 [113]. Genome-wide association studies have 
identified 163 distinct loci that confer risk of or protection from the development of CD and 
UC with a substantial portion of these loci (110 of 163) common to both diseases [114]. The 
genetic variants that have been found to confer CD risk point to the importance of innate 
immunity, autophagy and phagocytosis in CD pathogenesis. In particular, a number of genes 
associated with CD (IL23R, tyrosine-protein phosphatase non-receptor type 2 (PTPN2)) are 
also associated with other autoimmune disorders, suggesting that a subset of CD patients 
share common triggers with these conditions [88]. IBD-associated loci can be grouped into 
several important pathways including the innate immune response, maintenance of intestinal 
barrier function, autophagy, endoplasmic reticulum stress, microbial defence and antimicro-
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bial activity, goblet cell function, epithelial restitution, generation of reactive oxygen species, 
pathways that determine tolerance and training of innate immune cells, and maintenance of 
balance between T helper 17 (Th17) cells and regulatory T (Treg) cells [115].  
 Both CD and UC are typical chronic inflammatory processes of the gut which, by 
definition, are due to abnormalities of the intestinal immune system [116]. Both adaptive and 
innate immunity have role in the pathogeny of IBD.  Several decades ago it was discovered 
that the production of antibodies, particularly IgG antibodies, in the systemic as well as 
mucosal compartments was drastically increased and that the relative proportions of 
immunoglobulin classes and subclasses were altered as a consequence of chronic gut 
inflammation [116, 117]. For many years the cause of IBD has been attributed to a 
deregulation of the adaptive immune system, however in recent years the main focus is on 
innate immune system. In patients with NOD2 mutations, the activation of NF-kB in response 
to MDP is defective and the expression antimicrobial factors are decreased, enabling com-
mensal bacteria to trigger inflammation [118]. Recent findings also suggest that so-called 
‘healthy bacteria’ or probiotic combinations can ameliorate IBD, however these observations 
remain to be confirmed in larger clinical studies and are currently not considered as major 
treatment options [119, 120]. In turn, more aggressive bacteria that in contrast to pathogens 
by itself do not cause a disease in normal hosts, but that would trigger or increase inflamma-
tion in hosts with genetic and environmental risk factors have been associated with IBD. 
These bacteria are called pathobionts and a classic example described in CD is that of ad-
herent-invasive Escherichia coli (AIEC), a phenotypic strain suited to thriving in the context 
of CD with a predilection for ileal disease [121]. As the name suggests, AIEC can adhere and 
invade host mucosa resulting in bacterial replication and a disproportionate expansion of 
these organisms. A second adherent, invasive bacterium, Campylobacter concisus, has also 
been associated with IBD [122, 123].  C. concisus invasion affects membrane permeability 
and drives inflammation in host epithelial cells. These findings suggest that members of the 
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Proteobacteria phylum might have unique abilities that enable them to exploit host defenses 
and promote proinflammatory change in susceptible hosts [121]. 
1.8 Dextran sodium sulfate induced colitis 
Animal models of intestinal inflammation can be divided formally into four categories: 
(i) spontaneous models, (ii) inducible models in mice with a normal immune system, (iii) 
adoptive transfer models in immunocompromised hosts and (iv) transgenic mice [124]. 
Chemical-induced models of gut inflammation are the most commonly used and best de-
scribed models of IBD, especially Dextran sulphate sodium (DSS), Trinitrobenzene sulfonic 
acid (TNBS) and dinitrobenzene sulfonic acid (DNBS) induced colitis.  
TNBS or DNBS should be given to mice, rats or rabbits by by intrarectal instillation in 
ethanol [124]. Ethanol is required to break the mucosal barrier, whereas TNBS is believed to 
haptenize colonic autologous or microbiota proteins rendering them immunogenic to the host 
immune system [125]. As CD4+ T cells have been shown to play a central role in chronic 
TNBS colitis, this model is useful to study T helper cell-dependent mucosal immune 
responses [125], whereas DNBS-induced colitis allows one to study the pathogenesis of IBD 
associated environmental triggers such as stress and diet [124].  
DSS is administrated in drinking water of animals. Depending on the concentration, 
the duration and frequency of administration of DSS, the animals may develop an acute or 
chronic colitis. Feeding mice for several days with 0, 5 up to 5% of DSS in the drinking water 
induce an acute colitis with bloody diarrhoea, ulcerations, histological damage, and infiltra-
tions of neutrophils with severity of symptoms depending of dosage. DSS can be adminis-
trated in several cycles (7 days DSS, 7 days water) resulting in chronic colitis with chronic 
lesions with infiltrating macrophages, CD4+ T lymphocytes, and fissuring ulcers. The 
advantages of DSS-induced colitis model are many clinical and pathological similarities to 
human IBD especially UC [126]. It exhibits the inflammation–dysplasia–adenocarcinoma 
sequence and has also been shown to respond to standard human IBD medical therapeutic 
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measures such as steroids and anti-TNF antibody [127]. Like human IBD, there is also a 
variable genetic susceptibility of various mice strains to DSS-induced colitis and involvement 
of multiple genetic loci [128]. Also, acute and chronic, model can be easily produced by 
changing the concentration of administration of DSS (and cycle in rats and other strains of 
mice) [126] The potential drawback of this model the wide range of molar weight (MW) of 
dextran used in the induction of colitis. The MW of DSS is an important factor that deter-
mines the site and severity of inflammation in this model [129]. Another potential weakness 
of this model is the less clearly defined involvement of the normal enteric bacterial flora, un-
like in many other experimental IBD models [129]. 
The exact mechanism through which DSS induces colitis is still unknown. One possi-
bility is DSS direct alteration of gut permeability. Tight junction proteins such as zona oc-
cludens-1 were directly reduced by DSS as early as day 1, leading to increased permeability 
by day 3, changes that preceded colonic inflammation [130, 131]. The other suggested 
mechanism is a concentration, time, and cell type dependent cytotoxicity on intestinal epithe-
lial cell lines and intraepithelial lymphocytes hybridomas (IELH cells) or fresh IELs [132]. 
IELH were more sensitive than epithelial cells, and fresh IELs were the most sensitive. Also, 
DSS affect the expression of adhesion molecules and disrupts the normal interaction be-
tween IELs, epithelial cells and extracellular matrix [132].  
1.9 The c-Jun N-terminal kinases 
The c-Jun N-terminal kinases, members of the mitogen-activated protein kinase 
(MAPK) family were initially called stress activated protein kinase (SAPK) because they are 
activated by a variety of environmental stresses. MAPK pathways are conserved amongst all 
eukaryotes and play key roles in almost every physiological or pathophysiological process, 
they control the pheromone response in yeast and hormonal signalling in plants, as well as 
neuronal differentiation, apoptosis and inflammation in mammals [133]. MAPK pathways are 
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pivotal elements of the control network which orchestrates all stages of inflammation, from 
the detection of microbial invasion or the loss of tissue integrity via the recruitment of 
leucocytes to the resolution of inflammation characterized by apoptosis of immune cells, 
extracellular matrix repair and normalization of tissue physiology [134].  
MAPK kinases are made of three subgroups p42/44 extracellular signaling kinase 
(ERK), c-Jun N-terminal kinases (JNKs) and p38 MAP kinases. JNKs are activated in re-
sponse to stimuli such as inflammatory cytokines, bacterial products, oxidative stress, patho-
logic and environmental stress (ischemia, hypoxia, as well as UV and ionizing radiation), 
toxins, drugs, ER stress, and metabolic changes, including obesity and hyperlipidemia [135]. 
The upstream pathway leading to JNK activation is a complex process governed by different 
signaling proteins. Actually, JNK phosphorylation is mediated mitogen activated protein ki-
nase kinase kinases (MAP3Ks), which then phosphorylate and activate MAP3K isoforms 
mitogen activated kinase kinases (MKK4 and MKK7), which in turn phosphorylate and acti-
vate JNKs. JNKs phosphorylate c-Jun at NH2-therminal Ser63 and 73 residues, and thus 
named c-Jun N-terminal kinases. In addition to c-Jun, JNKs can phosphorylate and activate 
transcription factors such as JunB, JunD, AF2, p53, c-Myc, Itch, IRS-1, JIP-1, Bcl-2, Bcl-xL, 
Bid, Bim, Bad, Bax, and Mcl-151 playing an important role in a variety of cellular processes, 
including cell proliferation, differentiation, and apoptosis [135-137]. The exact function of 
JNKs is cell type/tissue specific and depends on physiological condition. The JNKs are 
encoded by three genes, Jnk1, Jnk2, and Jnk3. JNK1 and JNK2 are ubiquitously expressed, 
whereas the expression of JNK3 is restricted to the brain, heart and testis [138]. JNK1 gene 
is on chromosome 14, while JNK2 gene is present on chromosome 11. Each JNK is ex-
pressed as a short form (46kDa) and a long form (54kDa), which have overlapping but also 
distinct biological functions. The JNK signalling pathways are regulated by upstream regula-
tors (e.g. MAP3Ks), down-stream inhibitors (e.g. phosphatases), and scaffold proteins (e.g. 
c-Jun-amino-terminal kinase-interacting proteins (JIPs)) [139]. TAK1 is crucial for JNK acti-
vation in response to inflammatory cytokines and also for activation of Toll-like receptors 
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(TLR-3, TRL-4 and TLR-9), the B cell receptor and T cell receptor [139]. Studies with knock-
out mice showed that the members of MAPK phosphatase (MKP) are negative regulators of 
JNK signaling either by direct interaction or mediated by scaffold protein [139].  MKP 
isoforms may be directly targeted to JNK, but these interactions may also be mediated by 
scaffold proteins. For instance, the JNK phosphatase MKP7 has been found to form com-
plexes with the JNK scaffold proteins b-arrestin 2 and JIP1 [140]. There is a large body of 
evidence that JNKs mediate pro-apoptotic functions. They target pro-apoptotic B cell lym-
phoma2 (Bcl-2) proteins and regulate the transcription of pro-apoptotic genes such as Tnf, 
FasL and Bcl-2 homologous antagonist/killer (Bak) [141]. Concomitant stimulation of rat in-
testinal cell line (IEC6 cells) with TNF and DNA-damaging agent cytidine tryphosphate in-
duced JNK activation and apoptosis, whereas JNK inhibitor (SP600125) blocked the effects 
of TNF and CTP [142]. However, there are also examples of survival signalling controlled by 
JNK. JNK1/JNK2 double-knockout mice are lethal and embryos show strongly elevated 
apoptosis in the forebrain [143]. JNK1 promotes the survival of BCL/Abl-transformed B lym-
phoblasts in association with increased expression of anti-apoptotic Bcl2 [144] and enhanc-
es the proliferation of hepatocellular carcinoma cells by down regulating p21 [145]. Upon 
treatment of U937 cells with two known ER stressors, tunicamycin (N-glycosylation inhibitor) 
and thapsigargin (inhibitor of Ca2+ release from ER), JNK2 expression was increased, 
whereas pharmacological inhibitor or silencing of JNK2 caused caspase 3 activation and cell 
death [146]. Upon ER stress JNK2 protects cells against apoptosis by preventing accumula-
tion of the acidic/lysosomal compartment during undergoing autophagy. 
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1.10 Aim of this study 
The JNK pathway plays an important role in various inflammatory disorders therefore 
the it is considered to be a potentially relevant target for therapy for IBD[134, 147]. JNK 
regulates the maturation and activity of T cells and synthesis of pro-inflammatory cytokines 
such as interleukin-2 (Il-2), interleukin-6 (Il-6) and Tnf [134, 147].  
Genome-wide association studies (GWAS) have clearly linked IBD to specific biologi-
cal processes such as innate immune sensing, autophagy, Th17 response and cellular sig-
nalling including NfB or MAPK pathways [148]. Several IBD risk loci are associated with 
genes that influence JNKs. Examples for these are NOD2, tumor necrosis factor (ligand) 
superfamily, member 9 and 15 (TNFSF9/15) and mitogen-activated protein kinase kinase 
kinase 8 (MAP3K8) [149-152]. Increased JNK activation was observed in human colonic 
tissues of IBD patients shown by ELISA and immunostaining [153, 154]. Phospho-JNK was 
present in the intestinal cells, macrophages and lymphocyte, localized predominantly in the 
nucleus in IBD patients [147]. JNK inhibitors are studied for their potential role in a therapy 
for IBD in humans and mice. There are a great number of different small molecule JNK in-
hibitors that have been published or patented. These inhibitors either affect JNK signaling 
(e.g. CEP 1347) or block the catalytic domain of JNK (e.g. SP600125) [147]. The TAT-fused 
JNK-inhibiting peptide XG-102 (D-JNKI-1) was tested for its therapeutic potential in TBNS 
Figure 3 The JNK signalling pathway. Modi-
fied from Roger J. Davis. The JNK and p38 MAPK 
are activated by dual phosphorylation on Thr and 
Tyr caused by members of the MAPKK group of 
protein kinases. The MAPKK are activated, in 
turn, by phosphorylation mediated by a group of 
MAPKKK. 
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induced colitis in mice [155]. The subcutaneous injection of XG-102 significantly and dose-
dependently attenuated the clinical parameters, pathological changes, immune cells infiltra-
tion and cell death. Culturing mononuclear cells or colonic tissue with SP600125 down-
regulated inflammatory cytokine production [154]. Prophylactic treatment with SP600125 
significantly reduced clinical and pathological scores in DSS-treated rats and mice suggest-
ing that inhibiting JNKs phosphorylation could benefit patients with inflammatory bowel 
disease [154, 156]. Nevertheless, genetic deletion of either JNK1 or JNK2 aggravated the 
development of DSS-induced colitis in mice [157]. JNK1 and JNK2 deficient mice received 
three cycles of DSS treatment, each consisting of 1.7% DSS for 5 days, followed by 5 days 
with water and after 30 days animals were sacrificed. Aggravated colitis and increased mor-
tality in JNK2 deficient mice compared with controls and mild colitis with slight enhanced 
damage score in JNK1 deficient mice compared with controls were observed. Potential ex-
planation could be (i) moderate specificity of inhibitors for JNK and interference with other 
signaling pathways, (ii) an incomplete inhibition of JNK activity by pharmaceutical inhibitors 
that enables the blockage of pro-inflammatory pathway, whereas protective function may be 
preserved, or (iii) the functional redundancy of JNK1 and JNK2 that may account for the dif-
ferent phenotypes of single JNK-deficient animals compared to Pan-JNK inhibitors [147].  
In the need of clarifying the exact role of different JNK isoforms in specific compart-
ment in gut and mechanism by which JNK activation leads to intestinal inflammation in this 
study we focused on deciphering the function of the JNK genes in steady state and the DSS-
induced colitis. We tried to clarify the importance of the JNK pathway components as poten-
tial therapeutic targets for treating IBD. 
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
Name of the product Company 
100% Methanol  VWR 
2-[4-2-hydroxyethyl-1-piperazinyl]ethansulfonacid 
(HEPES) 
Merck 
 
2-Propanol Merck 
4-(2-Aminoethyl)-benzensulfonylfluorid (Pefabloc) 
 
Carl Roth 
Acetic acid (glacial) 100 % AppliChem 
Acetone J.T.Baker 
Agarose Invitrogen 
Ammonium acetate AppliChem 
Ammoniumpersulfate (APS) AppliChem 
Bromodeoxyuridine Sigma 
Bromophenol Blue Serva 
BSA (Bovine Serum Albumin) Sigma 
Calcium chloride (CaCl2) Sigma 
Chloroform Merck 
Dextran Sulfate Sodium salt MP Biomedicals 
Diethylpyrocarbonat (DEPC) Life Technologies 
Dimethylsulfoxide (DMSO) Merck 
Dipotassium phosphate (K2HPO4) Merck 
Dithiotreitol (DTT) Sigma 
Dodecylsulfate (SDS) Carl Roth 
Material and Methods 
36 
 
Eosine Sigma 
Ethanol 100 % AppliChem 
Ethidiumbromide (EtBr) Sigma 
FITC-Dextran TdB Consultancy 
Formaldehyde 37 % Carl Roth 
Gene RulerTM 1kb DNA Ladder New England Biolabs 
Glucose Merck 
Glutaraldehyde AppliChem 
Glycerol  Sigma 
Glycine AppliChem 
Haematoxylin / Eosin Merck 
Hexadecyltrimethylammonium bromide Sigma 
Hydrochloric acid (HCl) AppliChem 
Hydrogen peroxide 30% Applichem 
Ketamine Ratiopharm 
L-Glutamine Life Technologies 
Magnesium chloride (MgCl2) Sigma 
N,N,N’,N’-Tetramethylethylendiamine TEMED 
N,N;N’,N’-Ethylendiamine-tetraacetate (EDTA)        Calbiochem 
Nonidet P-40 Sigma 
o-dianisidine hydrochloride Sigma 
Paraformaldehyde Merck 
Ponceau Red Sigma 
Potassium chloride (KCl) Merck 
Potassium dihydrogen phosphate (KH2PO4) Merck 
Rabbit serum  Dako 
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Recombinant Mouse Myeloperoxidase R&D systems 
Rompun 
 
Bayer 
 
 
Roti-histokit Carl Roth 
Sodium acetate Carl Roth 
Sodium fluoride (NaF) Carl Roth 
Sodium hydroxide Carl Roth 
Sodium pyruvate Life Technologies 
Sodium vanadate (Na3VO4) Sigma 
SpectraTM Multicolor Broad Range Protein Ladder Thermo Scientific 
ß-Mercaptoethanol Applichem 
Tris Buffer grade AppliChem 
Triton X-100 Sigma 
TWEEN-20 Serva 
2.1.2  Enzymes, Reagents and kits 
Name of the product Company 
Accutase  
 
eBioscience 
Acrylamide Solution 30 % Biorad 
Affymetrix GeneChip WT Terminal Labeling Kit Affymetrix 
Ambion WT Expression Kit Ambion WT Expression 
Kit 
Ambion 
Avidin/Biotin blocking kit Vector 
BioRad Protein Assay Biorad 
Complete Mini, Protease Inhibitor Cocktail Tablets Roche 
Covering solution for cryo sections (Tissue-Tek®) Sakura 
Diaminobenzidine (DAB) Sigma-Aldrich 
DNA marker 1kb plus Ladder® Invitrogen 
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ECLTM Prime Western Blotting Detection Reagent GE Healthcare 
GeneJET RNA purification kit Thermo Scientific 
Hot Star Taq Master Mix Kit Qiagen 
In Situ Cell Death Detection Kit, Fluorescein Roche 
Mounting medium with DAPI Vector 
Omniscript RT PCR Kit Qiagen 
PeqGOLD-RNAPure® Peqlab 
Proteinase K AppliChem 
Red Taq Sigma 
RNeasy Lipid Tissue Mini Kit Qiagen 
SYBR® GreenER qPCR SuperMix Invitrogen 
Vectashield Mounting Medium with DAPI Vector laboratories 
Vectastain ABC kit Vector laboratories 
2.1.3 Antibodies 
2.1.3.1 . Primary antibodies for IHC, IF and WB  
Primary antibodies Company Origin Dilution 
Anti-BrdU GE Health Care Mouse 1:4000 
Anti-mouse  p-JNK1/2 Cell signalling  Rabbit 1:1000 
Anti-mouse Cd11b     AbD Serotec Rat 1:100 
Anti-mouse Cleaved 
caspase-3 
Cell Signaling 
 
 
 
 
 
Rabbit 1:1000 
Anti-mouse Gapdh Cell Signaling,  Rabbit 1:1000 
Anti-mouse JNK (FL) Santa Cruz 
Biotechnology 
Rabbit 1:1000 
Anti-mouse Lysozyme C Epitomics  Rabbit 1:1000 
Anti-mouse ZO-I                                                                        Invitrogen Rabbit 1:100 
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2.1.3.2 . Secondary antibodies for IHC, IF and WB 
Secondary antibodies Company Origin Dilution 
Anti-mouse IgG(H+L) Alexa 
488 
Invitrogen Goat 1:200 
Anti-rabbit IgG (H+L) Alexa 
488 
Invitrogen Goat 1:200 
Anti-rat IgG (H+L) Alexa 
546 
Invitrogen Goat 1:200 
Anti-rabbit IgG (H+L) Alexa 
546 
Invitrogen Goat 1:200 
Anti-rabbit IgG (H+L)-HRP Vector Laboratories Goat 1:200 
2.1.4 Instruments and equipment 
Name of product  Company 
7300 Real Time PCR System with 
Sequence Detection Software Version 1.3.1. 
Applied Biosystems 
Autoclave Varioklav SN40570475 HP Medizintechnik GmbH 
Blotter V20-SDB Semi-dry Biophoretics  
Cell culture centrifuge Megafuge 1.0R Heraeus 
Cell culture Incubator Heraeus 
Centrifuge 5415D Eppendorf 
Cooling centrifuge 5417R Eppendorf 
Cryostat HM 550 Microm 
ELISA Reader μQuant +KC4 Software BIO-TEK 
Endoscope  Karl Storz 
Eppendorf Research Pipette Eppendorf 
Gel Imager/Transilluminator BioDoc Analyze 
 
Biometra 
Homogenizer Ultra-Thurax® IKA laboratory 
LAS mini 4000 Fuji 
Microscope Axio Imager Z 1 Zeiss, Jena 
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Nanodrop reader Thermo Scientific 
Overhead shaker REAX 2 Heidolph 
pH Meter PB-11 Sartorius 
Power supply Power Pac HC BioRad 
Roller Mixer SRT 9 Stuart 
Rotating incubator Bachofer 
SDS PAGE electrophoresis system  PeQLab 
Shaking incubator Unimax 1010 Heidolph 
Thermoblock Eppendorf 
Thermocycler T3000 and Tpersonal Biometra 
Thermomixer 5436 Eppendorf 
Vortex IKA  laboratory 
Water bath Haake W13 Fisons 
2.1.5 Consumables 
Name of product Company 
96 well Microplates for RT-PCR  Star LAB 
96 wells Microplates for protein measurements Greiner 
96 wells Microplates for RNA measurements Greiner 
Cover glass Carl Roth 
Disposable scalpels sterile No. 11 Feather 
Eppendorf tubes 1ml, 1,5 and 2,0ml Eppendorf 
Falcon cell strainers Fisher Scientific 
Histology slides Thermo Scientific 
Multiply-PCR Strips Sarstedt 
Nitrocellulose membrane Protran® Whatman®, GE Healthcare 
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Super Frost slides Carl Roth 
Surgical instruments Aesculap 
Syringe Omnican® Braun 
Xylazin (Rompun®) Bayer 
2.2 Methods 
2.2.1 Human samples 
 Biopsies from colon sigmoideum were obtained from a total of nine patients with 
confirmed diagnosis of Ulcerative colitis (n=3), Crohn disease with mild inflammation (n=2), 
Crohn disease with strong inflammation (n=2) and control patients (n=2) during routine co-
lonoscopy at the University Hospital RWTH Aachen, fixed in 4 % PFA and embedded in 
paraffin. Patients provided written informed consent. The study was approved by the local 
ethics committee (reference number EK 049/12).  
2.2.2 Animal experiments 
2.2.2.1 Animal housing and breeding 
Animal were housed under standardized conditions in the “Institute for animal sci-
ence“ of the University Hospital of RWTH Aachen. A 12-hours light\dark cycle, controlled 
humidity of 50-60% and temperature of 20-24 °C was maintained. Mice had free access to 
water and food and they were kept in macrolon cages. All animal experiments were per-
formed according to the German legal requirements and animal protection law and were 
approved by the government of the state North Rhine-Westphalia (LANUV, Germany). 
2.2.2.2  Mice strains 
To investigate cell specific function of Jnk1 and Jnk2 genes in the regulation of 
mouse intestinal barrier function in vivo we used five mice genotypes. Mice with floxed al-
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lele of JNK1, conditional JNK1 knockout mice, complete JNK1 knockout mice, complete 
JNK2 knockout and double JNK1/ JNK2 knockout mice. Constitutive JNK1 and JNK2-
deficient mice defined in a C57BL/6 background were purchased from The Jackson Labor-
atory (JNK1−/− and JNK2−/−). Mice with a floxed allele of Jnk1 were constructed by using 
homologous recombination in ES cells and backcrossed to the C57BL/6J strain as 
previously described [158, 159]. Conditional JNK1 knockout mice (JNK1ΔIEC) are generated 
crossing transgenic Villin-Cre mice which express Cre recombinase under the Villin pro-
moter and mice that have floxed JNK1 allele. These mice were then crossed with JNK2-
deficient mice to create double knockout  JNK1ΔIEC/JNK2−/− mice. 
2.2.2.3 Dextran sulfate sodium colitis 
There are numerous and variable animal models of colonic inflammation that re-
sembles several features of IBD [160]. In our study we used chemically induced model of 
gut inflammation known as DSS colitis. Our mice were treated with 3% DSS over 7 days 
when they were sacrificed.  On day 6, mice were fasted for three hours and gavaged with 
100 µl FITC-labeled dextran (90mg/100g) and four hours later we collected the serum for 
further analysis. To determine proliferation rate 100µl Bromodeoxyuridine (3mg/ml) was 
given by intraperitoneal injection 2 hours before sacrificing. 
 
Figure 4 Experimental setup. 7 days of 3% DSS treatment, evaluation of weight change and 
stool consistency on day 0, 3, 5 and 7.  FITC-dextran gavage on day 6 and blood collection. Injection 
of BrdU 2 hours before sacrificing. 
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2.2.2.4 Evaluation of colitis 
Severity of experimental colitis was evaluated by the disease activity index (DAI) 
based on weight loss, stool consistency and rectal bleeding (divided by 3) as described 
elsewhere [161].  Each score was determined as follows, change in weight (0:<1%, 1: 1–
5%, 2: 5–10%, 3: 10–15%,  4: >15%), stool consistency (0:normal, 1:loose stools, 
2:diarrhea, 4:strong  diarrhea) and rectal bleeding was defined using the Hemokult test and 
scored from 0 to 4 (0: no bleeding, 1: slight bleeding, 2: mild bleeding, 4: strong bleeding). 
Bodyweight loss was calculated as the percent difference between the original bodyweight 
and the actual bodyweight on any particular day.  
After sacrificing the mouse, colons (without caecum) and small intestines were re-
moved and flushed with PBS. The terminal 1.5 cm were removed and used for RNA isola-
tion and myeloperoxidase (MPO) assay (see below). The remaining part was opened longi-
tudinally, rolled and cut longitudinally in two pieces. One part was fixed with 4% PFA and 
embedded in paraffin. The second part was embedded in TISSUE TEK. The tissue 
sections were stained with haematoxylin/eosin and examined under microscope. 
Histological images were evaluated independently by two investigators, blinded to the 
respective group. A histopathology score was determined semiquantitatively by the sum of 
the following criteria: (i) Epithelial damage (0: normal; 2: irregular epithelial cell morphology 
in <1/3 of total area; 4:irregular epithelial cell morphology in > 1/3 of total area and/or small 
erosions; 6: Presence of ulcers with <10% of ulcerated areas; 8: 10 -20 % of ulcerated are-
as; 10: >20% of ulcerated areas); (ii) Loss of goblet cell, (iii) inflammatory cell infiltration 
and (iv) submucosa thickening (for ii – iv; 0: normal; 1: mild ; 2: moderate; 3: severe). (Mod-
ified from Ryoichi Takayanagi & Akihiko Yoshimura, 2011) [162].Length of ileal villi was 
analysed in areas with optimal cutting orientation using ImageJ software and expressed as 
mean of at least 10 measured villi per animal. Goblet cells were quantified by PAS staining 
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2.2.2.5 Endoscopy scoring  
 The terminal colon of anaesthetised mice were investigated using a mini-
endoscope. Endoscopic score was evaluated according to the following criteria: (0: normal; 
1: erythema; 2: erosions, contact vulnerability; 3: larger ulcerations, spontaneous bleeding), 
as described previously [163].
 
2.2.3 DNA and mRNA analysis 
2.2.3.1 Genotyping of genetically modified mice with PCR 
To determine the genotype of mice, DNA from tail biopsies was isolated and PCR 
was performed. For DNA isolation, tail biopsies from young mice were lysed in 200 µl NID 
lysis buffer and 1 µl Proteinase K at 56°C overnight.  Proteinase K was inactivated at 95°C 
for 10 minutes. After mixing vigorously the lysate was centrifuged for 10 minutes with max-
imum speed. For PCR 2 µl of the supernatant containing DNA was used as template.  
NID lysis buffer: 
Substance Stock concentra-
tion 
Volume Final concentration 
Tris pH 8.3 1 M  10 ml  10 mM  
KCl  1 M  50 ml  50 mM  
MgCl2 1 M  2 ml  2 mM  
NP-40 - 4.5 0.45% 
Tween 20 - 4.5 0.45% 
Gelatine type III 10 mg/ml  10 ml  0.1 mg/l  
PCR reactions  were as follows: 
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Reaction volume 25 µl 
Primer sense (0,1nmol) 1 µl 
Primer antisense (0,1nmol) 1 µl 
Polymerase mix 12,5 µl 
dH2O 8,5 µl 
DNA template 2 µl 
PCR programs were as follows: 
Stage Cre PCR JNK1loxP PCR JNK1/2 PCR 
 
Denaturation 
Temp 
98°C  
 
Time 
2 
min 
Cycle Temp 
94°C 
Time 
1min 
Cycle Temp 
95°C 
Time 
15min 
Cy-
cle Denaturation 
Annealing 
Elongation 
  95°C 
54°C 
72°C 
 
15s 
45se
c 
45se
c 
1 94°C 
60°C 
72°C 
1min 
1min 
1min 
1 94°C 
53°C 
72°C 
15s 
30sec 
30sec 
1 
 35-
37 
Additional 
elongation 
  72°  5min  36 72°C 3min 36 72°C 2min 36 
C servation 4°C ∞  4°C ∞  4°C ∞  
Primer sequences were as followed: 
Target gene Primer name Sequence in 5’ – 3’ orientation 
Cre fw CCACGACCAAGTGACAGCAAT 
re TTCGGATCATCAGCTACACCA 
Jnk2 fw TCC AGT ACA GCG CGG CTG AA 
re GCA GCA GCC CTC AGG ATC CT 
fm TCT GAC GTC CTG GGC TGG AC 
Jnk1 fw CAC ATA CAC TCA GTG GAT CT 
re CAC TAT TGC CTT AAG ACT CC 
fm CTG ATC TTC CAG ATA ACT GC 
Jnk1loxP fw CCTCAGGAAGAAAGGGCTTATTTC 
re GAACCACTGTTCCAATTTCCATCC 
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PCR products were separated by size on 2% (w/v) agarose gels. The agarose was 
boiled in TAE buffer, cooled for 5-10 min at room temperature, and 0.4 μg/ml ethidium 
bromide (EtBr) was added. 5x loading dye were added to the samples before application to 
the gel slots. Gels were run in TAE at 100-150 V. DNA markers were used to determine the 
specific size of fragments. EtBr, which intercalates into the DNA, enables the visualisation 
of the DNA on a UV-transilluminator. 
2.2.3.2 Isolation of mRNA from intestinal tissue 
The small piece from from deep frozen intestinal tissue (about 50 mg) was trans-
ferred into 1 ml peqGOLD-RNAPure®. After homogenization the lysate was incubated for 5 
minutes at room temperature. Afterwards, 200 µl of chloroform was added and the mixture 
and vortexed thoroughly for 15 s. After incubation for 10 min at room temperature the lysate 
was centrifuged at 12000 rpm at 4 °C. The upper aqueous phase was transferred to a new 
collection tube. 1 volume of 70% ethanol was added and thoroughly mixed by vortexing. 
The mixture was pipetted into an GeneJET RNA Purification column in a 2 ml collection 
tube. The tube with column inside was centrifuged at 12000 rpm for 1 min at room tempera-
ture. The flow-through was discarded. 700 μl of Wash Buffer 1 was added to the GeneJET 
RNA Purification Column and centrifuged at 12000 rpm for 1 min. After discarding the flow-
through 600 μl of Wash Buffer 2 were pipetted into the GeneJET RNA Purification column 
and centrifuged centrifuged at 12000 rpm for 1 min. Second step was repeated with 250 µl 
of Washing buffer 2 for 2 min. At the last step 50 μl of nuclease-free water was pipetted into 
to the center of the GeneJET RNA Purification Column membrane and centrifuge at 12000 
rpm for 1 min to elute RNA. Purification column was discarded and RNA was store at -80°C 
until use.   
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2.2.3.3 Determination of nucleic acid concentration 
Isolated nucleic acid was diluted 1:50 in aqua bidest. (ddH2O) to measure the ex-
tinction at 260 nm (E260) with Nanodrop reader. The RNA concentration was calculated ac-
cording to the formula (RNA concentration = 40 x E260 / 1000 [µg/µl]), while the DNA con-
centration was based on the formula (DNA concentration = 50 E260 / 1000 [µg/µl]). The puri-
ty of nucleic acid was determined with an additional measurement of the optical density at 
280 nm (E280) and the ratio of E260 / E280 between 1.8 and 2.1 reflects a pure quality. 
2.2.3.4 Reverse Transcription (RT) 
To converse single-stranded mRNA into complementary DNA (cDNA) for further 
analysis of gene expression, reverse transcription was performed by using Omniscript RT 
Kit according to manufacturer’s recommendations. 
Component Volume / reaction 
10x Buffer RT 2 µl 
dNTP mix (5 mM each) 2 µl 
Oligo-dT primer 10 µM 2 µl 
Omniscript Reverse Transcriptase 1 µl 
Template RNA  2 µg 
ddH2O add 20 µl 
Temperature Time 
37 °C 60 min 
95 °C 5 min 
 
2.2.3.5 Quantitative real time PCR 
To analyze the transcriptional expression level of relevant genes real-time PCR was 
performed by using a 7300 Real-Time PCR System with SDS software (version 1.3.1) and 
a SYBR Green PCR Kit. The method ΔCt was used to analyze the relative changes in gene 
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expression from real-time quantitative PCR experiments [164]. Normalisation was done 
with GAPDH gene expression. 
Component Volume / reaction 
SYBR Green 12,5 µl 
Primer sense (10 nM) 0,5 µl 
Primer antisense (10 nM) 0,5 µl 
ddH2O 6,5 µl 
cDNA 5 µl 
The following primers were used to detect transcriptional expression level of target genes 
as indicated:  
Target gene Sequence in 5’ – 3’ orientation 
Gapdh CAACTTTGTCAAGCTCATTTCC 
TCCAGGGTTTCTTACTCCTTG 
Il-1β GACCTGTTCTTTGAAGTTGACG 
AGATTTGAAGCTGGATGCTCTC 
Tnfα GACCCTCACACTCAGATCATCTTCT 
CCACTTGGTGGTTTGCTACGA 
Il-6 TGGTCTTCTGGAGTACCATAGC 
CTCTGAAGGACTCTGGCTTTG 
Il-10 GCTGGACAACATACTGCTAACC 
GCTGGACAACATACTGCTAACC 
Muc2 CTGACCAAGAGCGAACACAA 
CATGACTGGAAGCAACTGGA 
Muc5ac GAGGCCAACAAGGTAGAGCACA 
TGGGACAGCAGCAGTATTCAGT 
Material and Methods 
49 
 
Muc5b GAGGTCAACATCACCTTCTGC 
TCTCATGGTCAGTTGTGCAGG 
Bip TCATCGGACGCACTTGGA 
CAACCACCTTGAATGGCAAGA 
Chop GTCCCTAGCTTGGCTGACAGA 
TGGAGAGCGAGGGCTTTG 
Xbp1_s 
 
AGA CAG CGC TTG GGG ATG GAT 
CCT GCA CCT GCT GCG GAC TC 
Mmp2 
 
GGC AAT GCA GAT GGA CAG CC 
CAT AGT CCT CGG TGG TGC C 
2.2.4 Affimetrix mRNA array 
 RNA was isolated from colonic tissue as described above. Probes (n = 3 per 
condition, each 300 ng) were prepared according to the Ambion WT Expression Kit and the 
Affymetrix GeneChip WT Terminal Labeling Kit manuals. The fragmented labeled sample 
was hybridized to a GeneChip® Mouse Gene 2.0 ST Array at 45°C for 16 hours at 60 rpm. 
Hybridised arrays were then washed and stained on Fluidics Station 450 (protocol 
FS_450_00007) and scanned on a GeneChip Scanner 3000 7G (both Affymetrix). The 
image data were analyzed with GeneChip Command Console Software (Affymetrix). Cell 
intensity files were analysed by using the geneXplain 3.0 platform (GeneXplain GmbH, 
Wolfenbüttel, Germany). Robust Multiarray Averaging  method was used for normalization. 
Principal component analysis (PCA) were performed to describe overall variation between 
samples. Differentially expressed genes between groups were computed using Limma (cut-
off fold change > 2 and  p < 0.1). The rather high p value was accepted to prevent high type 
II errors since only 3 samples per group were analysed. Gene ontology (GO) enrichment 
analyses of regulated genes were performed using a cut-off p < 0.01.  
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2.2.5 Isolation of intestinal epithelial cells from colonic tissue 
After separation of small and large intestine, removing Payer’s patches and residual 
mesenteric fat tissue and washing with PBS samples were cut longitudinally. Mucus was 
scraped off using a glass microscope slide by firmly drawing the edge of the slide along the 
entire length of the intestines. This was done repeatedly until very little material was coming 
off. Intestine were then cut into 2 mm slices in petri dish with pre-warmed CTCM (RPMI, 
10% FBS, Penn/Strep, L-glutamine, Sodium pyruvate, beta-mercaptoethanol, 25mM 
HEPES) and transferred in 50ml falcon tube. Intestine pieces were washed by sucking 
pieces into 25mL pipet and letting the media bubble up in the pipet for about 30s and after 
settling media was decanted at last 3x until the wash medium became clean. Tissue was 
than incubated for 30 min at 37° in Stripping buffer while shaking (1mM EDTA, 1mM DTT, 
1% BSA, Penn/Strep in PBS). After filtration through a 70 µm cell strainer and centrifuga-
tion at 400 rpm for 10 min the pellets contained colonic content with epithelial cells. Pellets 
were resuspended in 200 µl of NP40 buffer for protein analysis.  
2.2.6 Protein isolation and quantification 
Total proteins were isolated from intestine tissue (see Isolation of intestinal epithelial 
cells from colonic tissue) and extracted with ice cold NP40-Buffer containing 50 mM Tris-
HCl (PH 7.5), 150 mM NaCl, 0.5% NP-40 and 50 mM NaF freshly supplemented with pro-
tease inhibitors, phosphatase inhibitors and 1 mM DTT. Protein concentrations were de-
termined by BIO-RAD protein assay according to manufacturer’s instruction. Standard 
curve with 11 point 2-fold dilutions was prepared from BSA (bovine serum albumin) solution 
dissolved in water (highest St 1mg/ml). The absorbance of protein lysates and protein 
standard was measured at 595 nm and protein concentration was calculated according to 
the BSA standard curve.  
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2.2.7 Western blotting 
Samples containing 80 µg of protein were combined with 6x Laemmli sample buffer 
and boiled at 95°C for 5 min. Samples were separated by sodium dodecyl sulfate poly-
arylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred from gel 
to cellulose membrane using a semidry blotting system. Membranes were blocked for 1 h in 
blocking buffer (5% Dry-Milk in TBS-Tween) and then probed with appropriate antibodies in 
blocking buffer overnight at 4°C. After incubation membranes were washed with TBS-
Tween 3 times for 15 min and then incubated with a HRP-linked secondary antibody for 1 h 
in room temperature. Washing of membranes was performed 3 times for 15 min in TBS-
Tween and followed by incubating with ECL western blotting detection reagent. Proteins 
with ECL signals were detected by a digital detection system. GAPDH was used as loading 
control.  
2.2.8 Immunofluorescence (IF) 
2.2.8.1 Quantification of BrdU incorporation by immunofluorescence microscopy 
BrdU (5-bromo-2-deoxyuridine) incorporation and subsequent staining was used to 
quantify the number of cells in S-phase. For in vivo labeling, BrdU was injected i.p. (30 µg/g 
body weight) 2 h before animals were sacrificed. Pieces of intestine tissues were frozen in 
Tissue-Tek at -80°C. For staining, 7µm cryosections on Superfrost slides were made and 
then air-dried at room temperature for 1.5 - 2 h and fixed with prechilled acetone at -20°C 
for 10 min. After rehydration in 1x PBS for 5 min, slides were treated with 2 M HCl for 30 
min and then neutralized with 0.1 M sodium borate (pH 8.0) for 9 min. Slides were washed 
in tap water and in PBS for 3 x 10 min. After washing, samples were incubated with anti 
BrdU mouse monoclonal antibody (1:4000 dilution) at 4°C overnight. On the second day, 
slides were washed in PBS for 3 x 10 min and then incubated with anti-mouse Alexa 488 
antibody for 1 h at room temperature in the dark. Samples were then washed in PBS for 15 
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min and stained with phalloidin that binds actin filaments (2µg/ml in DMSO). After 30 min 
slides were washed in PBS for 3 x 10 min and mounted with DAPI containing mounting 
medium and covered with glass coverslips. The percentage of BrdU positive cells was 
counted with Image J Software. 
2.2.8.2 TUNEL staining 
TUNEL (TdT-mediated dUTP nick end labelling) staining is an established method 
for in situ labelling of DNA strand brakes that occur early during apoptosis. However, 
TUNEL staining is not specific for apoptotic cell death since also in necrotic cells DNA 
strand brakes occur. Terminal deoxynucleotidyl transferase (TdT) is used to introduce 
labelled nucleotides into partially degraded DNA. Intestine cryosections were fixed with 4% 
PFA for 45 min and rehydrated with PBS for 3 x 10 min. Sections were treated with 3% 
H2O2 in methanol for 10 min, and then permeabilized with 0.1% Triton 100x, 0.1% Na-
citrate for 2 min at 4°C. Slides were washed with PBS and stained with TUNEL mix (1μl 
enzyme, 9 μl TUNEL dilution buffer, 90 μl buffer) in humidified chamber overnight at 4°C. 
After 3 x 10 min washing with PBS stained sections were mounted with DAPI mounting 
medium. The percentage of TUNEL positive cells was counted with Image J Software. 
2.2.8.3 CD11b staining 
For staining, 7µm cryosections on Superfrost slides were made and then air-dried at 
room temperature for 1.5 - 2 h and fixed with prechilled acetone at -20°C for 10 min. After 
rehydration in 1x PBS for 5 min sides were blocked with 5% rabbit serum for 1 hour on 
room temperature. After removing the blocking solution samples were stained with primary 
antibody in humidified chamber overnight at 4°C. On second day after washing with PBS 
for 3 x 10 min secondary HRP-linked antibody was added for one hour on room tempera-
ture and after washing with PBS for 3 x 10 min stained sections were mounted with DAPI 
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mounting medium. The percentage of CD11b positive cells was counted with Image J 
Software. 
2.2.8.4 ZO-I staining  
Same protocol as described for CD11b staining was used with primary α-rabbit ZO-I 
antibody. 
2.2.9 Immunohistochemistry (IHC) 
Paraffin embedded sections were dewaxed and rehydrated with xylene and 
decreasing percentages of ethanol. Antigen retrieval was performed by cooking sections in 
10 mM sodium citrate buffer (ph 6.0) for 6 min in a microwave. After cooling for 10 minutes, 
sections were rinsed in running tap water and endogenous peroxidases were quenched for 
10 min. Sections were washed under running water, washed with PBS for 3 x 10 min. 
Following blocking with Avidin D blocking reagent for 15 min at RT and with Biotin blocking 
reagent for 15 min at RT, sections were blocked in PBT (PBS, 0.1% BSA, 0.2% TritonX-
100) and then incubated overnight with primary antibody at 4°C in a humid atmosphere. 
Slides were washed with PBS for 3 x 10 min and the secondary antibody was applied for 1 
hour at RT in a humidifying box. In parallel, HRP-ABC solution was made and incubated at 
least 30 min at RT prior to use. Sections were incubated with HRP-ABC solution for 1 hour 
at RT in a humidified box. After washing with PBS for 3 x 10 min, signal was developed 
with DAB and counterstained with hematoxylin. Dehydrating was performed increasing 
percentages of ethanol and xylene and slides were mounted with Roti-histokit. 
2.2.10 Myeloperoxidase assay 
Colonic tissue samples were homogenized in ice-cold potassium phosphate buffer 
(50 mM K2HPO4 and 50 mM KH2PO4, pH 6.0) containing 0.5% 
hexadecyltrimethylammonium bromide. The homogenates were freeze-thawed three times, 
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and centrifuged at 4000 rpm for 15 min. Supernatants (20 µl) or MPO standard were added 
to 1 mg/mL o-dianisidine hydrochloride and 0.0005% H2O2, and the change in absorbance 
after 3 min at 450 nm was measured. The results were calculated against a 2-fold serial 
dilution MPO standard and expressed as U/mg of tissue.  
2.2.11 In vivo permeability assay  
 Barrier function was assessed using the permeability tracer FITC-labeled dextran, 
described previously [165]. Mice were deprived of food for 3 h, and gavaged with 4 kD 
FITC-labelled dextran at 0.6 mg/g of body weight. Blood was retroorbitally collected after 4 
h, and fluorescence intensity in serum was measured (excitation, 492 nm; emission, 525 
nm). Standard curve with 11 point 2-fold dilutions was prepared from FITC-dextran dis-
solved in water (highest St 100μg/ml). 
2.2.12 Bone marrow transplantation 
  Bone marrow transplantation is a procedure of replacing damaged or de-
stroyed bone marrow with healthy bone marrow stem cells. Bone marrow cells (BMCs) 
were isolated from euthanized donor mice. Irradiation of recipient mice was performed by 
using a cobalt irradiator twice for a total dose of 13.6G. Lethally irradiated recipient mice 
received a single concentration of 107 donor BMCs /ml intravenously (tail vein). Recipient 
mice were maintained on antibiotic-containing water for 2 weeks. 
2.2.13 Statistics 
 Data are expressed as means (± SEM) or median (± interquartile range) as indicat-
ed. Statistical significance was analysed by Mann Whitney U test for comparison of two 
groups and by Kruskal-Wallis test followed by Dunn's post hoc test for the comparison of 
multiple groups. Statistical analyses were performed using GraphPad Prism. 
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3 Results 
3.1 Generation of knockout mice 
To investigate cell specific function of different JNK isoforms in the regulation of 
mouse intestinal homeostasis we generated mutant mice lacking each member of the JNK 
family. In the present study we used 5 groups of mice: conditional JNK1 knockout mice 
(JNK1∆IEC), constitutive JNK1 and JNK2 knockout mice (JNK1-/- and JNK2-/-), double knock-
out mice (JNK1∆IEC/JNK2-/-) and respective WT controls (floxed mice). To confirm the correct 
genomic changes of the respective knockout mice we performed PCR of DNA isolated from 
intestinal epithelial cells as well as from tail DNA (Figure 5).  
 
We first investigated activation of JNKs in patients by performed  immunohistochisto-
chemisty for p-JNK on human colon tissue samples and detected p-JNK, in patients diag-
nosed with ulcerative colitis, Crohn disease with mild inflammation, Crohn disease with 
strong inflammation but not in non-inflammatory controls (Figure 6A). We observed a corre-
lation between staining intensity and the grade of inflammation. P-JNK was localized pre-
dominantly in the cytoplasm and nuclei of IECs at the luminal side, but was also detectable 
in some crypt IECs and lamina propria cells (Figure 6A). 
Figure 5 PCR results confirm genomic 
modifications. DNA isolated from IECs (upper 
panel) and tails (lower panel) of WT, JNK1
∆IEC
, 
JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice were subject-
ed to PCR with Jnk1 and Jnk1
loxP
 specific pri-
mers.
 
1550 bp band indicates WT allele, 1095 
bp band indicates JNK1
loxP
 allele and 395 bp 
band indicates JNK1 after cre recombination. 
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To analyze the activation of different JNK isoforms in physiological and stress-related 
conditions in mice we stained colon tissue samples for p-JNK from WT, JNK1∆IEC, JNK2-/- 
and JNK1∆IEC/JNK2-/- mice after DSS treatment and non-treated controls. JNKs were phos-
phorylated in the nucleus of IECs of WT and JNK1∆IEC mice after DSS treatment, in addition 
JNK activation was detected also in cells of lamina propria (Figure 6B), however in colon 
samples of JNK2-/- and JNK1∆IEC/JNK2-/- mice we did not observe p-JNK activation. Expres-
sion of p-JNK proteins was also analyzed by western blotting. Low-level of pJNK was de-
tectable in WT mice in the absence of intestinal inflammation indicating a high sensitivity of 
western blot compared to IHC. Basal pJNK was partially reduced in JNK1IEC (mainly the 46 
kDa isoform) and JNK2-/- mice (mainly the 55 kDa isoform) and completely absent in 
JNK1∆IEC/JNK2-/-mice (Figure 6B and C). Upon DSS treatment we observed strong induction 
of p-JNK in WT and JNK1∆IEC but complete loss of p-JNK in JNK2-/- and JNK1∆IEC/JNK2-/- 
mice (Figure 6C). Total JNK was weakly reduced in JNK1IEC and strongly diminish in JNK2-/- 
mice in both non- and DSS-treated mice. It was completely absent in JNK1∆IEC/JNK2-/- mice. 
This data suggest that p-JNK isoforms in IECs are expressed from both Jnk1 and Jnk2 in 
physiological conditions, but mostly from Jnk2 during colitis.  
(A) 
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(B) 
 
(C) 
 
Figure 6 JNKs are activated during colitis in humans and mice. (A) IHC staining detecting p-
JNK1/2 antibody in human colon tissue from patients diagnosed with Ulcerative colitis, Crohn disease 
with mild inflammation, Crohn disease with strong inflammation and control patients without inflamma-
tion. (B) IHC staining of p-JNK antibody on WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/-   
colon sam-
ples upon DSS treatment and respective controls. Arrows indicate p-JNK positive cells. Scale bar = 
5µm. (C) Isolated proteins from ICEs from WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice after DSS 
treatment and respective controls were examined by Western blotting by probing with antibodies to p-
JNK and total JNK. 46 and 54 KDa bands indicate different JNK splicing forms. GAPDH were used as 
loading controls. 
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3.2 The role of JNKs in steady state 
3.2.1 JNK1 and JNK2 are not crucial for normal development and aging of 
mice 
In the first part of this study analysed the role of JNK isoforms in normal development 
of the intestine in young mice as well as during aging. Generally 10 weeks old JNK1∆IEC, 
JNK2-/- and JNK1∆IEC/JNK2-/- mice looked normal and healthy, there were no significant dif-
ferences in body weight, stool consistency, ability to reproduce and in general appearances 
between knockout mice and littermate controls (Figure 7). Mice were monitored over 45 
weeks and sacrificed at the age of 45 weeks. All mice appeared phenotypically normal with 
no difference in body weight (Figure 7), with no tumors or any macroscopical alterations. 
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Normal intestine architecture of 10 and 45 weeks old mice was observed after H&E 
staining, with no immune cells infiltrates and no difference in colon length (Figure 8). Inter-
estingly, 10 and 45 weeks old JNK1∆IEC/JNK2-/- mice exhibited a significant decrease in the 
length of villi in the mucosa of small intestine compared with control mice (Figure 8B-D).   
 
 
Figure 7  Normal development and aging 
in JNK-deficient mice. Body weight of 10 
and 45 weeks old WT, JNK1
∆IEC
, JNK2
-/-
 and 
JNK1
∆IEC
/JNK2
-/- 
mice are shown. Labelling: 1
-
 = 
JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
.   
Each dot represents one animal 
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(D) 
 
Figure 8 Histological analysis of ileum and colon of 10 and 45 weeks old WT, JNK1∆IEC, 
JNK2-/- and JNK1∆IEC/JNK2-/- mice. (A) Colon lengths of indicated mice are shown. (B) Changes 
in the length of villi analyzed after H&E staining. (C and D) Representative H&E images of ileal and 
colon sections of 10 and 45 weeks old mice. Scale bar = ileum 5µm and colon 20µm. Labelling: 1
-
 = 
JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
.  Each dot represents one animal. *: p<0.05 compared to 
WT analysed by Kruskal-Wallis and Dunn Post-hoc test. 
Maintaining homeostasis in the intestinal epithelium is a complex of interactions 
between the host and the microorganisms. Paneth and goblet cells play an essential role in 
keeping this equilibrium. Thus, we investigated whether JNK deficiency can impair the epi-
thelial cell defense. We stained ileum sections for Lysozyme C abundant in Paneth cells and 
observed no difference in Paneth cells numbers between WT and knockout mice (Figure 
9A). JNK deletion did not affect goblet cells number or genes expression of secretory mucins 
between the groups (Figure 9B-F). 
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(E)                                                                         (F)                                            
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Figure 9 Paneth cells, goblet cells and mucin expression in WT and JNK deficient 
mice. (A) Representative images of IHC staining for Lysozyme C,  Paneth cell marker, on ileal sec-
tions from WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice are shown. (B) Periodic acid Schiff (PAS) 
staining of colonic goblet cells. Scale bar = 5µm. (C) Graph represents percentage of PAS
+
 epithelial 
cells per total epithelial cells. (D-F) Muc2, Muc5ac and Muc5b mRNA expression in colonic tissue 
derived from untreated mice of indicated genotype. Expression levels were normalized to the expres-
sion of the housekeeping gene Gapdh. Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. 
Each dot represents one animal. 
 Intestinal epithelial cells have a high rate of cell turnover accompanied by an equally 
high rate of apoptosis [166]. Keeping the balance between proliferation and apoptosis is es-
sential for maintaining the homeostasis intestinal epithelium. To access the importance of 
JNKs on intestinal homeostasis, we performed BrdU incorporation assay on colon tissue 
sections. Proliferating cells were mostly located in crypt base and a significant increase in 
proliferation in JNK2-/- mice as well as JNK1∆IEC/JNK2-/- mice compared to WT controls was 
observed (Figure 10A). More than 12% of IECs were BrdU positive in JNK2-/- mice and more 
than 15% in JNK1∆IEC/JNK2-/- animals, while in JNK1∆IEC and WT mice only 6 % of IECs were 
BrdU-positive (Figure 10C). In order to analyze apoptosis we performed cleaved caspase 3 
immunohistochemical staining. We observed greater number of apoptotic cells in JNK2-/-  
and JNK1∆IEC/JNK2-/- mice compared with WT controls, although the results for JNK2-/  were 
not statistically significant (Figure 10B and D) Apoptotic cells were mainly located at the lu-
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minal surface. Overall, the results indicate an increased cell turnover in the absence of 
JNK2.  
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Figure 10 Enhanced IEC cell turnover in JNK2-deficient mice. (A) IF staining for BrdU 
(green), Phalloidin for F-actin (red) and DAPI staining for nuclei on colon sections from JNK1
∆IEC
, 
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JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice and aged-matched WT controls. Scale bar = 5 µm. (B) Colon 
sections were immunostained for cleaved caspase 3 (brown) and counterstained with haematoxylin 
(blue). Scale bar = 5µm. (C) Quantification of BrdU positive cells was performed with Image J. (D) 
Quantification of cleaved caspase 3 positive cells. Graphs represent percentage of positive IECs per 
total IEC. Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. Each dot represents one ani-
mal. Lines indicate medians. *: p<0.05 compared to WT analysed by Kruskal-Wallis and Dunn Post-
hoc test. 
Previous studies showed an important role of JNKs in maintaining epithelial barrier 
function in both physiological and pathophysiological states in vitro through regulation of 
epithelial tight junction (TJ) and adherents junction (AJ) proteins [167-169]. JNK deletion 
does not affect basal level of gut permeability in vivo measured by FITC-uptake (data not 
shown, below detection limit) and the colonic expression of zonula occludes protein-1 (ZO-I), 
which connects actin cytoskeleton with transmembrane proteins of tights junctions, in 
JNK1∆IEC, JNK2-/- and JNK1∆IEC/JNK2-/- mice, suggesting that JNK deletion does not alter 
epithelial barrier function under homeostatic conditions (Figure 11). 
 
Figure 11 Tight junction protein ZO-I expression in JNK knockout mice. IF staining of 
ZO-I (red) and DAPI staining for nuclei (blue) on frozen colon sections of WT, JNK1
∆IEC
, JNK2
-/-
 and 
JNK1
∆IEC
/JNK2
-/- 
mice. Arrows indicated ZO-I protein. Scale bar = 5µm. 
 We observed no difference in the expression profile of pro-inflammatory Tnf-α, Il-1β, 
Il-6 or anti-inflammatory Il-10 cytokines (Figure 12). Furthermore, MPO activity in tissue ho-
mogenates of WT and JNK-deficient mice was below the detection limit indication absence 
of infiltration of neutrophils (data not shown). Overall, these data show that JNK-deficiency in 
IECs does not induce spontaneous inflammation or barrier dysfunctions. 
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Figure 12 No inflammation in JNK deficient mice. (A/B/C/D) mRNA expression in colonic 
tissue derived from untreated  WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice for Tnf-α, IL-1β, Il-6 
and Il-10 were determined by RT-PCR. Expression levels were normalized to expression of the 
housekeeping gene Gapdh and presented as log2. Labelling: 1- = JNK1∆IEC; 2-= JNK2-/-; 1/2-= 
JNK1
∆IEC
/JNK2
-/-
. Each dot represents one animal. Lines indicate medians. 
3.3 JNK2 protects against acute colitis  
3.3.1 JNK2-deficient mice are highly susceptible to DSS-induced colitis  
To investigate the role of JNKs in stress related conditions we orally administered 3% 
of DSS for 7 days to induce acute colitis. WT and JNK1∆IEC suffered from mild body weight 
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loss of about10% at day 7. JNK2-/- mice lost around 15%, while JNK1∆IEC/JNK2-/- mice lost 
about 20% of body weight after 7 days of DSS treatment (Figure 13A). Moreover, both JNK2-
/- and JNK1∆IEC/JNK2-/- had more pronounced bloody stool with strong diarrhea presented as 
disease activity index score (DAI score) (Figure 13B). 
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           Figure 13 JNK2-/- mice suffer from severe DSS-induced colitis. (A) The effect of oral 
administration of 3% DSS on body weight in WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice.  (B)  
Disease activity index (DAI) scoring weight loss, stool consistency and rectal bleeding of WT, 
JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice were analysed at 7 day of DSS treatment. Statistics was 
performed with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks above dots indicate statisti-
cal differences between WT and respective genotype. Other differences are indicated by lines. * p < 
0.05; ** p < 0.01; *** p < 0.001. 
H&E stained colon sections of DSS-treated mice on day 7 revealed alteration of 
epithelial structure with severe lesions throughout the mucosa, loss of goblet cells, pro-
nounced edema with ulcers and immune cells infiltration into the mucosal and submucosal 
areas in JNK2-/- and JNK1∆IEC/JNK2-/- mice compared to WT and JNK1∆IEC mice (Figure 14A). 
All changes, observed by a blinded observer, were combined to obtain histopathological 
score (Figure 14B) indicating very severe colitis with epithelial destructions and inflammation 
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in JNK2 deficient mice compared with WT as well as JNK1∆IEC, correlating with disease activ-
ity index. 
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We further analyzed by PAS staining for goblet cells and real-time PCR for secretory 
mucins. JNK2-deficient mice had strong reduction of goblet cells (Figure 15A and B) and 
decrease of Muc2 gene expression, which the main secretory mucin in the intestinal tract. 
Expression of Muc5ac and Muc5b were not significantly changed (Figure 15C). Interestingly, 
we also observed also a tendency for reduced Muc2 expression in non-treated JNK2-/- and 
JNK∆IEC mice, although these data did not reach statistical significance (see Fig. 9D). 
Figure 14 JNK2 gene deletion aggravates DSS in-
duced colitis. (A) Representative images of colon tissue 
sections stained with H&E of WT, JNK1
∆IEC
, JNK2
-/-
 and 
JNK1
∆IEC
/JNK2
-/- 
 mice showing extensive  ulcers  with loss 
of epithelial and goblet cells, submucosa thickening and 
infiltration of the immune cells. Scale bar =20µm.(B) Histo-
pathology score at day 7 of DSS treatment. Labelling: 1
-
 = 
JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. Bars indicate 
means. Statistics was performed with Kruskal-Wallis test 
and Dunn Post-hoc analysis. Asterisks above bars indicate 
statistical differences between WT and respective genotype. 
Other differences are indicated by lines. * p < 0.05; ** p < 
0.01; *** p < 0.001.  
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Figure 15 Decrease of Goblet cells and mucin 2 expression in JNK2 deficient mice 
after DSS administration. (A) Periodic acid Schiff (PAS) staining for goblet cells was performed 
on paraffin embedded colon sections of WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/-
 mice. Scale bar = 
5 µm. (B) Graph represents percentage of PAS
+
 epithelial cells per IECs. (C) mRNA expression in 
colonic tissue for Muc2, Muc5ac and Muc5b were determined by RT-PCR. Expression levels were 
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normalized to expression of the housekeeping gene Gapdh and presented as log2. Labelling: 1
-
 = 
JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. Each dot represents one animal.  Lines indicate medi-
ans. *: p<0.05 compared to WT analysed by Kruskal-Wallis and Dunn Post-hoc test. 
3.3.2 Enhanced proliferation and apoptosis in JNK2-deficient mice 
To investigate the relevance of JNKs for cell turnover under stress conditions we per-
formed BrdU incorporation assay for proliferation and IHC for cleaved caspase 3 as a mark-
er of apoptosis. We observed that IEC cell turnover was overall increased during acute DSS 
colitis with increased proliferation of IECs in colons of JNK2-/- and JNK1∆IEC/JNK2-/- mice 
compared to WT and JNK1∆IEC mice (Figure 16A and C). As in non-treated animals JNK2-
deficient mice exhibited higher rates of IEC apoptosis as compared to WT and JNK1∆IEC mice 
(Figure16B and D ). 
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Figure 16 Enhanced IEC cell turnover in JNK2-deficient mice after DSS treatment. (A) 
IF staining for BrdU (green), Phalloidin that binds F-actin (red) and DAPI staining for nuclei (blue) on 
colon sections of WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice. (B) IHC staining for cleaved 
caspase 3 (brown) and counterstained with haematoxylin (blue). (C) Quantification of proliferating 
(BrdU positive) IECs. (D) Quantification of apoptotic (cleaved caspase 3 positive) cells.
 
Percentages 
of positive IECs per total IEC are shown. Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. 
Each dot represents one animal. Lines indicate medians. Statistics was performed with Kruskal-Wallis 
test and Dunn Post-hoc analysis. Asterisks above dots indicate statistical differences between WT 
and respective genotype. Other differences are indicated by lines. * p < 0.05; ** p < 0.01; *** p < 
0.001. 
 Increased cell death rate of IECs examined by cleaved caspase 3 staining was con-
firmed by TUNEL staining, which stains apoptotic and necrotic cells. Most TUNEL-positive 
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cells were found in ulcerative areas (data not shown), these lesions contain many necrotic 
ulcerativ areas were excluded from the analysis. TUNEL-positive cells were analyzed in the 
areas were epithelial lining remained intact. JNK2-/- and JNK1∆IEC/JNK2-/- mice showed signif-
icantly more TUNEL-positive cells than WT and JNK1∆IEC with cells localized mostly on the 
tip of the colon tissue (Figure 17). 
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3.3.3 Strong inflammatory response in JNK2 deficient mice 
One of the hallmarks of DSS induced colitis is infiltration of immune cells into the lam-
ina propria. To investigate whether JNK deletion affects the inflammatory response we per-
Figure 17 Increased number of TUNEL-positive cells in 
DSS-treated JNK2-deficient mice. (A/B) TUNEL staining  
frozen sections of WT, JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice after DSS treatment with quantification. Graph represents 
percentage of positive IECs per total IECs. Labelling: 1
-
 = 
JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. Each dot represents 
one animal.  Lines indicate medians. Statistics was performed 
with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks 
above bars indicate statistical differences between WT and re-
spective genotype. Other differences are indicated by lines. * p < 
0.05; ** p < 0.01. 
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formed IF staining for CD11b. CD11b is a leukocyte-specific receptor and is regarded as a 
marker for monocyte/macrophages, granulocytes, and natural killer cells [170]. We observed 
significant increased influx of CD11b positive cells into lamina propria of JNK1∆IEC/JNK2-/- 
mice compared with WT animals (Figure 18A and B). To confirm this data we investigated 
the MPO enzymatic activity in cell lysates (Figure 18C) and expression of pro-inflammatory 
cytokines Tnf-α and Il-1β (Figure 18D and E). MPO is myeloperoxidase enzyme, abundant in 
neutrophils and therefore index of neutrophils infiltration. The results indicate a more pro-
nounced infiltration of immune cells and expression of pro-inflammatory cytokines in 
JNK1∆IEC/JNK2-/- mice as well as in JNK2-/- mice compared with WT control animals (Figure 
18). 
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Figure 18 Increased inflammation in JNK2-/- and JNK1∆IEC/JNK2-/- mice after DSS treat-
ment. (A) Representative images of CD11b immunofluorescence staining on frozen sections of WT, 
JNK1
∆IEC
, JNK2
-/-
 and JNK1
∆IEC
/JNK2
-/- 
mice (red) and DAPI staining for nuclei (blue). Scale bar = 
20µm. (B) Graph show area density of red staining analyzed using Image J Software. (C) Enzymatic 
activity of MPO was measured in cell lysates as an index of neutrophil infiltration into injured tissue. 
(D and E) mRNA expression in colonic tissue for Tnf-α and Il-1β was determined by RT-PCR. Expres-
sion levels were normalized to expression of the housekeeping gene Gapdh and presented as log2. 
Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
.  Each dot represents one animal Statistics 
was performed with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks above bars indicate 
statistical differences between WT and respective genotype. Other differences are indicated by lines. 
* p < 0.05; ** p < 0.01; *** p < 0.001. 
 
 
3.3.4 Colonic transcriptome analysis in WT, JNK1∆IEC and JNK2-/- mice 
 In order to to analyse the transcriptional profiles in DSS-induced colitis we performed 
Affimetrix mRNA arrays in colonic tissue derived from WT, JNK1∆IEC and JNK2-/- mice. The 
profiles of the three genotypes were clearly distinguishable by principle component analysis 
(Figure 19A). We found that the number of regulated genes was higher in the JNK2-/- vs 
JNK1∆IEC then in the JNK2-/- vs WT comparison (Figure 19B). 
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Figure 19 WT, JNK1∆IEC and JNK2-/- mice have distinct transcriptional profiles. Affimetrix 
mRNA arrays were performed from colonic tissue of 7 days DSS-treated WT, JNK1
∆IEC
 and JNK2
-/-
 
mice (n = 3 per group). (A) Transcriptional profiles of different genotypes are discriminated by princi-
ple component analysis. The first two components (PC1 and PC2) indicating 21% and 17% of overall 
variability, respectively, are shown. (B) Up- and downregulated genes of pairwise comparisons 
(JNK1
∆IEC
 vs WT, JNK2
-/-
 vs WT and JNK2
-/-
 vs JNK1
∆IEC
). 
Gene ontology (GO) enrichment analysis showed that many regulated genes of the 
JNK2-/- vs WT and JNK2-/- vs JNK1∆IEC comparisons belong to biological processes that are 
involved in inflammation, stress response, and extracellular functions such as tissue remod-
elling. In accordance with enhanced IEC apoptosis and proliferation in JNK2-/- mice, several 
genes involved in apoptosis and proliferation were differentially regulated JNK2-/- compared 
to WT and JNK1∆IEC mice. JNK1∆IEC vs WT regulated genes show a very different GO profile 
with a strong enrichment in intracellular processes such as nucelasome and macromolecular 
complex assembly. Together, the results showed that JNK1 and JNK2 kinases regulate dis-
tinct transcriptional profiles during acute colitis (Figure 20A).  Detailed analyses of regulated 
genes linked to the GO terms “negative or positive regulation of apoptotic process”, howev-
Results 
75 
 
er, revealed that anti-apoptotic genes show a mixed pattern of higher and lower expression, 
whereas the majority of pro-apoptotic genes were upregulated (Figure 20B-D). 
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Figure 20 Mapping of regulated genes to gene ontology (GO) categories and mRNA 
array data for genes involved in apoptotic regulation. (A) Absolute and relative numbers 
within selected categories are shown. (B-D)  Fold change (JNK1
∆IEC
 vs WT and JNK2
-/-
 vs WT) of 
genes classified in the GO categories “negative, positive and negative/positive regulation of apoptotic 
process. 
We confirmed by qPCR elevated expression of proinflammatory citokines (data 
shown elsewhere) as well as as matrix metalloproteinase 2 (Mmp2) (Figure 21A) and, in 
addition, of the ER-stress related genes Bip and Xbp1_s but not Chop in DSS-treated JNK2-
deficient mice (Figure 21B-D). However, in non-treated healthy mice above mentioned 
genes were not differentially expressed (Figure 21). 
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Figure 21  Tissue remodelling and activation of ER stress genes in non-treated and 
DSS-treated mice. mRNA expression in colonic tissue for Mmp2, Bip, Xbp1_s and Chop  were 
determined by RT-PCR and  expression levels were normalized to expression of the housekeeping 
gene Gapdh and presented as log2. Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
. Each 
dot represents one animal. Lines indicate medians. Statistics was performed with Kruskal-Wallis test 
and Dunn Post-hoc analysis. Asterisks above bars indicate statistical differences between WT and 
respective genotype. Other differences are indicated by lines. * p < 0.05; ** p < 0.01; *** p < 0.001.  
3.3.5 JNK2 gene deletion alters barrier function in stress condition 
One of the key features of homeostasis in the gut is intact gastrointestinal barrier. 
Tight junction proteins are essential for epithelial barrier integrity and seem to play a pivotal 
role in intestinal homeostasis [171]. These proteins act as a semipermeable gate and can 
regulate the passage of molecules between epithelial cells [172]. The colonic mucus was 
investigated in several studies of patients with colonic inflammation and was found to differ 
from controls and was less effective as a barrier [173, 174]. To analyze intestinal barrier in-
tegrity and mucosal permeability upon DSS treatment we gavaged mice with 60mg/100g 
body weight of fluorescently labeled Dextran (FITC-Dextran) molecular weight 4000. Four 
hours after the gavage we collected the blood retroorbitally and measured the presence of 
FITC-Dextran in the serum in the fluorimeter at 520 nm. FITC-Dextran concentration was 
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calculated according to standard curve with 11 point 2-fold dilutions with the highest stand-
ard of 100μg/ml prepared from FITC-dextran dissolved in water. We observed markedly in-
creased concentrations of FITC-dextran in the sera of JNK2-defficient mice compared to WT 
and JNK1 conditional knockout mice, indicating enhanced permeability of the intestinal bar-
rier for high molecular weight compunds (Figure 22A).  To further investigate the epithelial 
barrier we analyzed expression of tight junction proteins occludin and ZO-1  [175].  Reduced 
expression of these proteins in JNK2-/- and JNK1∆IEC/JNK2-/- mice showed by western blot-
ting and immunostaining revealed the crucial role of JNK2 in maintaining barrier function 
(Figure 22B and C). 
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Figure 22 Increased intestinal permeability of JNK2-/- and JNK1∆IEC/JNK2-/- mice after 
DSS treatment. (A) Changes in gut permeability measured by FITC-dextran tracer assays at day 6.  
Labelling: 1
-
 = JNK1
∆IEC
; 2
-
= JNK2
-/-
; 1/2
-
=
 
JNK1
∆IEC
/JNK2
-/-
.
 
Each dot represents one animal. Lines 
indicate medians. Statistics was performed with Kruskal-Wallis test and Dunn Post-hoc analysis. As-
terisks above bars indicate statistical differences between WT and respective genotype. Other differ-
ences are indicated by lines. * p < 0.05; ** p < 0.01. (B) WB analysis with Abs specific for occludin of 
colonic ICEs-derived proteins isolated from 7 days DSS-treated WT, JNK1
∆IEC
, JNK2
-/-
 and 
JNK1
∆IEC
/JNK2
-/-
. GAPDH were used as loading controls. (C) IF staining for ZO-I protein of colon sec-
tions from indicated mice after 7 days of DSS treatment. 
3.4 The importance of JNK2 gene in non-hematopoietic cells during 
DSS induced colitis 
3.4.1 Bone marrow transplantation 
Our results showed that JNK2 gene has leading role in ameliorating acute colitis, and 
we speculated that the key role of this kinase is in non-hematopoietic cells. Due to the lack 
of a floxed JNK2 mouse bone marrow transplantation (BMT) between WT and constitutive 
JNK2 knockout mice were performed to investigate this hypothesis. Mice were lethally irradi-
ated and reconstituted with either WT or JNK2 deficient bone marrow (JNK2-/-→WT and 
WT→JNK2-/-) and respective WT controls received BM from mice with same genotypes 
(WT→WT, JNK2-/-→JNK2-/-). Eight weeks after BMT chimerism in blood was confirmed by 
PCR showing successful reconstitution of BM cells (Figure 23). Two months after BMT, re-
cipient mice received 3% DSS over 7 days and then were sacrificed.  
(A)                                                             (B) 
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Figure 23 Creation of chimeric WT/JNK2-/- mice. (A) Scheme of the chimeras used in the 
study and the experimental setup of the study. (B). Ethidium Bromide gel showing the respective PCR 
results from blood DNA isolated 8 weeks after BMT from WT and JNK2
-/- 
reconstituted with WT and/or 
JNK2-deficient bone marrow. Size of WT allele is 700bp and JNK2Δ allele is 840bp. Two samples per 
experimental group are shown. 
3.4.2 JNK2 gene in non-hematopoietic cells aggravates DSS-induced colitis 
 At day 7 of DSS-induced colitis we observed a severe colitis with body weight loss of 
around 15 percent in chimeric mice with a JNK2-/- background reconstituted with BM from 
WT or JNK2-/- mice (Figure 24A). In contrast, WT mice reconstituted with bone marrow de-
rived from WT ()  orJNK2-/- (JNK2-/-→WT) mice had mild colitis with loss of less than 10 per-
cent of initial body weight. Moreover, we saw an increased DAI score in mice caring deletion 
of JNK2 gene in non-hematopoietic cells in comparison to WT→WT and JNK2-/-→WT mice 
(figure 24B). JNK2-/-→WT mice had only a slightly, however, not significantly elevated DAI 
score compared to WT→WT mice.        
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Figure 24 JNK2 deletion in non-hematopoietic cells exacerbates DSS-induced colitis. 
(A) The effect of oral administration of 3% DSS on body weight in WT→WT, JNK2
-/-
→JNK2
-/-
, 
WT→JNK2
-/- 
and
 
JNK2
-/-
→WT mice. (B) Disease activity index (DAI) scoring weight loss, stool con-
sistency and rectal bleeding were analysed after 7 day of DSS treatment.  Statistics was performed 
with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks above dots indicate statistical differ-
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ences between WT→WT and respective genotype. Other differences are indicated by lines. * p < 
0.05; ** p < 0.01.  
We performed H&E staining and observed enhanced inflammation and ulcerative tis-
sue destruction in in chimeric WT→JNK2-/- and in JNK2-/-→JNK2-/compared to WT→WT and 
JNK2-/-→WT mice. Microscopic changes correlated with macroscopic signs of inflammation 
and ulceration observed by mouse endoscopy (Figure 25). 
(A) 
 
(B) 
 
 
 
 
 
 
Results 
82 
 
(C)                                                                          (D) 
w
t

w
t
w
t
-
2
-
2
-
2
-
2

w
t
0
5
10
15
Edema
PMN infiltration
Gob.cells loss
Erosion
***
**
* ***
19
H
is
to
p
a
th
o
lo
g
y
 s
c
o
re
(u
n
it
s
)
                     
w
t

w
t
w
t
-
2
-
2
-
2
-
2

w
t
0
1
2
3
4
*
*
*
E
n
d
o
s
c
o
p
y
 s
c
o
re
(u
n
it
s
)
 
Figure 25 JNK2 in non-hematopoietic cells protects against DSS colitis. (A) Representa-
tive images of colon tissue sections stained with H&E from WT→WT, JNK2
-/-
→JNK2
-/-
, WT→JNK2
-/- 
and
 
JNK2
-/-
→WT
 
animals showing huge ulcers with loss of epithelial and goblet cells, submucosal 
thickening and infiltration of the immune cells. Scale bar = 20 µm. (B) Mice were examined using en-
doscope after DSS treatment. (C) Histopathology score of colons after 7 days of DSS treatment in 
indicated mice. (D) Endoscopy score combined of the loss of vascularity, the appearance of bleeding 
and the mucosal erosions (ulcers). Labelling: 2
-
= JNK2
-/-
. Statistics was performed with Kruskal-Wallis 
test and Dunn Post-hoc analysis. Asterisks above bars and dots indicate statistical differences be-
tween WT→WT and respective genotype. Other differences are indicated by lines. * p < 0.05; ** p < 
0.01; *** p < 0.001.  
 
Analysis of cell turnover in colon samples of chimeric mice revealed that loss of 
JNK2 in the non-hematopoietic compartment was mainly responsible for increased prolifera-
tion and cell death of IECs (Figure 26). 
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Figure 26 Mice with JNK2 deletion in non-hematopoietic cells have increased cell 
turnover after DSS treatment. (A) Immunofluorescence staining for BrdU (green), Phalloidin for 
F-actin (red) and DAPI staining for nuclei on colon sections. Scale bar = 5µm. (B) Quantification of 
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BrdU positive cells was done with Image J Software (C) Cell death analysis by cleaved caspase 3 
immunohistochemistry in paraffin embedded colon sections of indicated mice. Scale bar = 5µm. (D) 
Quantification was done with Image J Software. Labelling: 2
-
= JNK2
-/-
. Each
 
graph represents per-
centage of positive IECs per total IEC. Each dot represents one animal. Lines indicate meadians. 
Statistics was performed with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks above dots 
indicate statistical differences between WT→WT and respective genotype. Other differences are indi-
cated by lines. * p < 0.05; ** p < 0.01. 
Furthermore, we checked infiltration rate of neutrophils into lamina propria by 
measuring MPO enzymatic activity,proinflammatory cytokines gene expression and epithelial 
barrier permeability. MPO activity, expression levels of Tnf-α and Il-1  in colonic tissue was 
strongly elevated in WT→JNK2-/- and JNK2-/-→JNK2-/- compared to JNK2-/- →WT and 
WT→WT mice, constant with the overall inflammatory phenotype of these animals (Figure 
27A-C). Moreover, FITC-Dextran uptake confirmed that JNK2 gene in non-hematopoietic 
cells has major role in protecting epithelial barrier in colon during stress conditions (Figure 
27D). 
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Figure 27 Strong immune response and impairment of barrier function the intestine of 
mice with JNK2 deletion in non-hematopoietic cells. (A) Enzymatic activity of MPO was 
measured in cell lysates from chimeric mice. (B and C) mRNA expression in colonic tissue for Tnf-α 
and Il-1β was determined by RT-PCR. Expression levels were normalized to expression of the house-
keeping gene Gapdh and presented as log2. (D) Changes in gut permeability measured by FITC-
dextran tracer assays at day 6. Labelling: 2
-
= JNK2
-/-
. Each dot represents one animal. Lines indicate 
medians. Statistics was performed with Kruskal-Wallis test and Dunn Post-hoc analysis. Asterisks 
above dots indicate statistical differences between WT→WT and respective genotype. Other differ-
ences are indicated by lines. * p < 0.05; ** p < 0.01. 
3.5 Complete JNK1-deficiency does not alter DSS colitis phenotype 
To investigate the role of JNK1 in non-IECs during acute DSS-induced colitis we studied 
a constitutive JNK1 knockout mice (JNK1-/-).  JNK1-/- mice and control littermates were orally 
administrated with 3% DSS over 7 days. No significant changes in weight loss or DAI score 
between the WT and JNK1 deficient mice were observed (Figure 28). 
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 Figure 28  Similar phenotype in DSS-treated WT and JNK1-/- mice. (A) The effect of oral 
administration of 3% DSS on body weight change in WT and JNK1
-/-
 mice. (B) Disease activity index 
(DAI) scoring weight loss, stool consistency and rectal bleeding were analysed after 7 days of DSS 
treatment. No significant difference between the groups. 
To confirm the finding that complete JNK1 deletion does not exasperate colitis pheno-
type we analysed histological changes in colons of WT and JNK1-/- mice after DSS treatment 
and observed no significant differences the epithelial architecture neither in immune cells 
between WT and JNK1-/- mice (Figure 29A and C) indicating that complete deletion of JNK1 
gene has no impact on colon mucosa upon DSS treatment. In order to further support this 
observation we performed mouse endoscopy and observed signs of mild colitis with no dif-
ference in endoscopy score between WT and JNK1-/- mice (Figure 29B and D). 
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Figure 29 Mild DSS-induced colitis in JNK1 deficient mice. (A) Representative H&E images 
of colon sections from WT and JNK1
-/- 
mice. Scale bar = 20. (B) Representative colonoscopy images 
of indicated DSS-treated mice. (C) Histopathology score at day 7. Medians of n = 4 are shown. (D) 
Endoscopy score is shown. Each dot represents one animal. Lines indicate medians. 
To exclude the effect of complete JNK1 deletion during DSS-induced colitis on cell 
turnover we performed BrdU incorporation assay and immunohistochemical cleaved-
caspase 3 staining. No differences in proliferation or apoptosis rates in IECs between WT 
and JNK1-/- mice were observed. This indicates that JNK1 in IECs and non-IECs do not play 
a major role in protection against DSS-induced  injury (Figure 33). 
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Figure 30 JNK1 deletion does not alter cell turnover after DSS treatment. (A) Immunoflu-
orescence staining for BrdU (green), Phalloidin that binds F-actin (red) and DAPI staining for nuclei on 
colon sections of WT and JNK1
-/-
 mice. Scale bar = 5µm. (B) Cleaved caspase 3 IHC staining on par-
affin embedded colon samples performed. Scale bar = 5µm. (C and D) Quantification of BrdU positive 
cells was done with Image J Software (D) Quantification of cleaved caspase 3 positive cells was done 
with Image J Software. Each dot represents one animal. Bars indicate medians.
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4 Discussion 
In the present study we describe that JNK2 mediates cytoprotective functions in IECs 
during homeostasis and in DSS-induced colitis.  
We first examined whether JNK phosphorylation was greater at the site of intestinal 
inflammation by performing IHC staining of human and mice colon samples. Activation of 
JNK was observed in IECs of IBD patients, but not in control patients with intensity of stain-
ing correlated with level of inflammation in IBD patients. Reduced activation of JNKs in non-
treated mice, as well as JNK2-deficient mice implied that JNKs were activated in inflammato-
ry tissue, but to a less extant in steady state and that p-JNK in DSS colitis was mainly en-
coded by JNK2 gene. IHC data were supported by western blotting of isolated epithelial 
cells. These results confirm published data that the JNK signaling pathway is highly activat-
ed in sites of IBD involvement [147, 153, 154]. 
IEC-conditional and constitutive JNK1 knockout mice were healthy with normal epi-
thelial architecture of small and large intestine without spontaneous tumours up to 45 weeks 
of age, although it has been suggested in previous studies that JNK1-deficient mice develop 
colonic adenomas [176]. These mice did not have any disequilibrium in cell turnover in phys-
iological condition or upon DSS treatment. Although it has been shown that JNK1 can medi-
ate pro-inflammatory functions in immune cells [177] and has disease aggravating functions 
in other inflammatory conditions e.g. of the liver triggered by JNK1 expressed in hematopoi-
etic cells or stellate cells [137, 178, 179], we did not identify a significant influence of JNK1 in 
IECs or non-IECs on the DSS colitis phenotype.  
In steady state JNK2-deficient mice exhibited elevated IECs turnover with increased 
apoptosis and proliferation rates as well as shortening of villi in the ileum. Villus shortening 
has been associated with enhanced epithelial apoptosis and regenerative response [68], 
whereas primary hyperproliferation observed in mice with an overexpression of a constitu-
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tively active JNKK2-JNK1 fusion protein is associated with villus elongation [180]. We 
strongly suggest that JNK2-deficient animals primarily suffer from increased IEC apoptosis 
rates with secondary elevated regenerative proliferation. Our results are in partial discrepan-
cy with data published in 2014 (after start of this work). In accordance with our data showed 
Chang et al.  that constitutive JNK2 knockout mice had higher proliferation of IECs within the 
ileal crypts and disrupted mucosal maturation with shorter villi length. However, in contrast to 
our finding they describe the same rate of spontaneous and reduced rate of stress-induced 
(TNF treatment) induced IEC apoptosis [181]. Currently, we cannot explain the differences of 
our findings. However, it is known that intestinal microbiota have a strong influence on the 
intestinal phenotype. Therefore, it is possible that differences in the local microbiota might be 
responsible for these differences.  
To our surprise, we did not detect an additional phenotype in animals with a com-
bined JNK1/2 knockout in IECs (JNK1∆IEC/JNK2-/-). The phenotype of these animals was very 
much comparable to JNK2-/- mice suggesting that JNK2 is more important for the IEC home-
ostasis and that JNK1 cannot compensate for the loss of JNK2. 
Upon DSS treatment JNK2 knockout mice suffered from severe acute colitis with 
bloody stool and strong diarrhea, inflammation, alteration of epithelial structure and in-
creased cell turnover indicating an important role for JNK2 in protecting mice from acute 
colonic injury induced by DSS. A recent study with conditional JNK1 and JNK2 knockout 
mice showed that cyclic administration of low-dose DSS (1%) induced chronic colitis in 
JNK2-deficient mice but not in JNK1-deficient mice. [182, 183]. After higher dose of 1,7% 
DSS JNK2-deficient mice had stronger colitis with enhanced morbidity and mortality while  
JNK1-deficient mice showed histological changes [182, 183]. However, the responsible cell 
types or underlying mechanisms were not investigated in these studies. In our model of 
acute colitis JNK2-deficient mice had strong inflammation with significantly elevated expres-
sion Tnf-α, Il-1β but not IL-6. BMT experiments clearly established the protective function of 
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JNK2 in non-hematopoietic cells, which most likely are IECs. These results are in contrast 
with experiments with pan-JNK inhibitor SP600125 [184] and the small peptide JNK1 inhibi-
tor XG-102 [155] showing that pharmaceutical inhibition of JNK signalling pathway improves 
the disease in mice and rodents. Thus, one of our initial hypotheses was that the divergent 
results could be due to the fact that pharmacological inhibition by SP600125 targets all JNK 
isotypes, whereas in the recent knockout studies only one JNK subtype was deleted. How-
ever, our results showing that a combined JNK1/JNK2 deletion in IECs did not improve the 
DSS colitis phenotype challenges this theory. In our opinion, there are three possible expla-
nations for the divergent results of the pharmacological inhibition and genetic deletion stud-
ies. First, inhibitors may only partially block JNKs thereby inhibiting pro-inflammatory while 
maintaining IEC cytoprotective functions. Second, a total inhibition of all JNKs in immune 
cells may be required to constitute anti-inflammatory effects. However, we have not tested a 
combined JNK1/JNK2 knockout in the immune cell compartment. And the third reason could 
be that JNK inhibitors have off-target effects that mediate anti-inflammatory and cytoprotec-
tive functions. Indeed, SP600125 targets several other kinases although higher concentra-
tions are required [185]. Noteworthy, our unpublished results show that SP600125 mediate 
cytoprotective functions in isolated JNK1/JNK2-deficient hepatocytes (Cubero JC et. al., un-
published results). Defining these potential JNK-independent SP600125 targets is of major 
interest because they might be interesting candidates more specific pharmacological inter-
ventions. 
  Defective intestinal epithelial barrier has been shown to be a pathogenic factor in 
the development of intestinal inflammation [169]. Dynamic remodeling of intercellular 
junctions (TJ and AJ) was disturbed by JNK activation in human colonic epithelial cell lines, 
using SP600125 inhibitor and JNK activator anisomycin [186]. Also in mammary epithelial 
cells inhibition of basal JNK activity enhanced epithelial barrier function modulating claudin 
expression [187]. Our results show an intact intestinal barrier and normal ZO-1 expression in 
JNK-deficient animals in steady state, but impaired barrier functions und reduced ZO-1 ex-
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pression in JNK2-deficient mice compared to WT and JNK1-deficients animals during acute 
colitis. In addition, we found decreased Muc2 expression and goblet cells numbers in JNK2-
deficient animals suggesting that mucin expression and/or goblet cell survival may be under 
the control of JNK2. However, our data cannot completely differentiate between primary 
JNK2-mediated processes and secondary effects caused by exaggerated inflammation upon 
DSS-induced colitis in JNK2-deficient animals. 
Our data reveal some insight why JNK1 and JNK2 have different effects on IECs. 
First, their expression and phosphorylation is differentially regulated in IECs. JNK2 is more 
strongly expressed, however, under physiological conditions basal p-JNK belongs to both, 
JNK1 and JNK2 at almost equal amounts. Upon colitis induction, JNK2 becomes strongly 
phosphorylated whereas the JNK1 phosphorylation status remains unchanged. This indi-
cates a more pronounced relative JNK1 phosphorylation during steady state, whereas JNK2 
phosphorylation is induced upon stress related conditions. Second, our data also clearly 
show that JNK1 and JNK2 mediate different downstream functions. Although during homeo-
stasis very similar amounts of phosphorylated JNK1 and JNK2 are present in IECs only the 
deletion of JNK2, but not JNK1 causes enhanced IEC turnover. Furthermore, the microarray 
data indicate that JNK1 and JNK2 regulate different transcriptional profiles during acute coli-
tis. Although enhanced inflammation and tissue destruction in JNK2-/- mice may be respon-
sible for a large number of regulated genes, we observed only a minor overlap between dif-
ferentially regulated genes in JNK2-/- and JNK1IEC mice emphasising the assumption that 
primary downstream target genes of JNK1 and JNK2 are diverge.  
We have clearly defined inhibition of spontaneous and stress-related apoptosis as a 
functional downstream function of JNK2, however, the molecular targets mediating this effect 
remain to be identified. Recent studies have suggested a crosstalk of JNKs and Wnt signal-
ling mediated by c-jun [180]. We found a partial reduction of c-jun phosphorylation in IECs of 
JNK1∆IEC/JNK2-/- mice, whereas it remains detectable in JNK2-/- mice (data not shown) sug-
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gesting that protective JNK2 effects are not solely mediated by c-jun. Furthermore, c-jun 
knockout mice how a reduced spontaneous proliferation of IEC what is the oposite phenoty-
ope that was observed in JNK2-/- and JNK1∆IEC/JNK2-/- mice [180]. Overall, the data suggest 
that the phenotype of JNK2-deficient mice cannot be explained by a deficient c-jun-
dependent signalling.  
The microarray data show multiple downregulated anti-apoptotic and upregulated 
pro-apoptotic genes in JNK2-/- mice. Upon these are several interesting candidates that may 
contribute to the observed phenotype. For example, Atonal homolog 1 (Atoh1) is downregu-
lated in JNK2-/- mice and has been shown to mediate intestinal secretory (including goblet) 
cell differentiation [188]. The Atoh1 promotor has potential bindings sites for the transcription 
factors Elk-1, Pax-2 and NFATs (analysed with MatInspector, Genomatix, data not shown) 
which are JNK downstream targets [189].  
In summary, the present work provides a comprehensive analysis of JNK functions in 
the intestinal tract and has identified JNK2 as an important cytoprotective factor in IECs, 
whereas JNK1-deficiency alone or in combination with JNK2 -had no impact. Our study pro-
vides a link to some of the recently identified MAPK-related genetic variations in IBD patients 
such as MAP3K8 [148]. 
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